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Abstract: The nuclear factor erythroid 2-related factor 2 (NRF2)–Kelch-like ECH-associated protein 1
(KEAP1) regulatory pathway plays an essential role in protecting cells and tissues from oxidative,
electrophilic, and xenobiotic stress. By controlling the transactivation of over 500 cytoprotective
genes, the NRF2 transcription factor has been implicated in the physiopathology of several human
diseases, including cancer. In this respect, accumulating evidence indicates that NRF2 can act
as a double-edged sword, being able to mediate tumor suppressive or pro-oncogenic functions,
depending on the specific biological context of its activation. Thus, a better understanding of the
mechanisms that control NRF2 functions and the most appropriate context of its activation is a
prerequisite for the development of effective therapeutic strategies based on NRF2 modulation.
In line of principle, the controlled activation of NRF2 might reduce the risk of cancer initiation
and development in normal cells by scavenging reactive-oxygen species (ROS) and by preventing
genomic instability through decreased DNA damage. In contrast however, already transformed
cells with constitutive or prolonged activation of NRF2 signaling might represent a major clinical
hurdle and exhibit an aggressive phenotype characterized by therapy resistance and unfavorable
prognosis, requiring the use of NRF2 inhibitors. In this review, we will focus on the dual roles
of the NRF2-KEAP1 pathway in cancer promotion and inhibition, describing the mechanisms of
its activation and potential therapeutic strategies based on the use of context-specific modulation
of NRF2.
Keywords: NRF2-KEAP1; ROS; cancer metabolism; antioxidant; oxidative stress; cancer therapy;
chemoresistance; radioresistance
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1. Introduction
Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor and a key modulator
of cellular antioxidant responses that regulates the expression of genes encoding antioxidant enzymes
with a protective role against different types of oxidative changes. NRF2 in combination with its
own negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), has become the center of a
debate regarding whether NRF2 suppresses the tumor promotion or, conversely, exerts pro-oncogenic
functions. Based on this, the present review will describe the role of NRF2 in cancer prevention
and promotion, discussing potential advantages and disadvantages derived from its therapeutic
modulation in cancer prevention and treatment. As it is known, under non-stressed conditions, NRF2 is
constitutively poly-ubiquitinated by the CUL3-KEAP1 E3 ubiquitin ligase complex and subjected to
degradation through the proteasome pathway [1]. After exposure to several redox altering stimuli,
highly reactive thiols of KEAP1 are subjected to instant modification, leading to NRF2 stabilization
caused by its decreased affinity for the CUL3-KEAP1 complex. Subsequently, NRF2 translocates into
the nucleus and binds to the antioxidant response element (ARE) located within the promoter region
of specific target genes, inducing the expression of a large number of cytoprotective proteins with
antioxidant and detoxifying roles [2–5]. The importance of NRF2 function has been demonstrated by
several studies using NRF2-deficient mice showing an increased susceptibility to redox disturbances
and xenobiotic stress [6–8]. It has also been shown that tissue oxidative damage after ischemia and
reperfusion is efficiently counteracted by NRF2 induction [9]. In line with the protective roles of
the KEAP1-NRF2 pathway, its activation seems to effectively prevent carcinogenesis by promoting
a number of antioxidant mechanisms [10,11]. Thus, NRF2 activation may have beneficial role as
a result of its suppressive effect on carcinogenesis. On the other hand, increasing evidence show
that constitutive NRF2 activation contributes to the progression of various cancer types. Specifically,
many studies have shown that the increased activation of NRF2 in cancer cells leads to its augmented
transcriptional activity and promotes tumor progression [12–14], metastasis formation [15], resistance to
chemo-radiotherapy [16–19], and is clinically associated with poor prognosis [20]. During the last
decade, several mechanisms through which NRF2 signaling pathway is persistently activated in
different types of cancers have been discussed. Regarding NRF2, its oncogenic activity promotes
cancer cell growth and proliferation, suppression of cancer cell apoptosis, self-renewal of cancer
stem cells, therapy resistance, increased angiogenesis and anti-inflammatory activities [21]. As the
pro-tumorigenic role of this factor has gained interest, pharmacological modulation of the NRF2
pathway offers pioneering therapeutic opportunities against several diseases. Recent studies have
brought to light a few small molecules displaying promising properties in NRF2 inhibition, but their
applicability still needs to be further investigated [22–25]. Most of these molecules lack specificity
and have off-target toxic effects since they easily react with cysteine residues of different molecules.
Metabolic instability, low bioavailability, and poor membrane permeability are some of the basic
drawbacks in the administration of many NRF2 inhibitors [26]. To date, dimethyl fumarate is the
only NRF2 activator approved by the Food and Drug Administration (FDA) but its function in cancer
prevention has not been examined yet.
Structure and Function of NRF2 and KEAP1
Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcriptional factor encoded by theNFE2L2
gene that belongs to “Cap’N’Collar” type of basic region leucine zipper factor family (CNC-bZIP) [27].
Human NRF2 protein is 605 amino acids long and contains seven conserved NRF2-ECH homology
domains known as Neh1-Neh7 [27,28]. Neh2 is a major regulatory domain located to N-terminus of
NRF2 and it has two binding sites known as DLG and ETGE. These sites help to regulate NRF2 stability
by interacting with the Kelch domains of E3 ubiquitin ligase Kelch-like ECH-associated protein 1
(KEAP1), a substrate of Cullin 3-based ubiquitin E3 ligase complex that ubiquitinates and targets NRF2
for proteasomal degradation [29–32]. The Neh1 and Neh6 domains have also been shown to control
NRF2 stability. The Neh1 contains a basic leucine zipper motif that is also known as DNA binding
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domain and it enhances NRF2 transcriptional activation [27,33]. The Neh6 domain is a serine-rich
domain containing two motifs (DSGIS and DSAPGS) that negatively modulate NRF2 stability through
beta-TrCP dependent but KEAP1 independent regulation [34]. The Neh3, Neh4, and Neh5 domains
are known as trans-activation domains of NRF2. The carboxy-terminal Neh3 domain binds to CHD6
(a chromo-ATPase/helicase DNA-binding protein) that is the transcriptional co-activator of NRF2 [35].
The Neh4 and Neh5 domains interact with the CH3 domains of CBP (CREB-binding protein) that
facilitates transactivation of NRF2 target genes [36,37]. In addition, a seventh domain of NRF2 known
as Neh7 has been shown to interact with a nuclear receptor retinoic X receptor alpha (RXRa) that
inhibits NRF2 target genes transcription [38]. A schematic representation of NRF2 structure is shown
in Figure 1A.
Antioxidants 2020, 9, 193 3 of 47 
modulate NRF2 stability through beta-TrCP dependent but KEAP1 independent regulation [34]. The 
Neh3, Neh4, and Neh5 domains are known as trans-activation domains of NRF2. The carboxy-
terminal Neh3 domain binds to CHD6 (a chromo-ATPase/helicase DNA-binding protein) that is the 
transcriptional co-activator of NRF2 [35]. The Neh4 and Neh5 domains interact with the CH3 
domains of CBP (CREB-bi ding protein) that facilitates transactivation of NRF2 target genes [36,37]. 
In addition, a seventh domain of NRF2 known as Neh7 has been shown to interact with a nuclear 
receptor retinoic X receptor alpha (RXRa) that inhibits NRF2 target genes transcription [38]. A 
schematic representation of NRF2 structure is shown in Figure 1A. 
 
Figure 1. Domain architectures of Kelch-like ECH-associated protein 1 (KEAP1) and nuclear factor 
erythroid 2-related factor 2 (NRF2). (A) Human NRF2 protein is 605 amino acids long and contains 
seven Neh domains. The Neh1 contains a basic leucine zipper motif that is responsible for 
dimerization with sMaf protein and ARE sequence binding in DNA. Neh2 has two binding sites 
known as DLG and ETGE that control KEAP1 interaction. The Neh6 domain is a serine-rich domain 
containing two motifs (DSGIS and DSAPGS) that negatively regulate NRF2 stability. The Neh7 
domain interacts with a nuclear receptor RXRα. The Neh3, Neh4, and Neh5 domains are known as 
trans-activation domains of NRF2. (B) KEAP1 is a 69-kDa protein and contains five domains. The BTB 
domain is critical for KEAP1 dimerization and recruitment of Cul3-based E3-ligase. The IVR domain 
has hypercritical cysteine residues, Cys273 and Cys288 that are essential for controlling NRF2 activity. 
Kelch/DGR domain negatively regulates NRF2 activation by interacting with conserved carboxyl 
terminus of Neh2 domain. BTB, broad complex, tram-track and bric-a-brac; CTR, C-terminal region; 
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Figure 1. Domain architectures of Kelch-like ECH-associated protein 1 (KEAP1) and nuclear factor
erythroid 2-related factor 2 (NRF2). (A) Human NRF2 protein is 605 amino acids long and contains
seven Neh domains. The Neh1 contains a basic leucine zipper motif that is responsible for dimerization
with sMaf protein and ARE sequence binding DNA. Neh2 has two binding sites kn wn as DLG
and ETGE that control KEAP1 interaction. The Neh6 domain is a serine-rich domain containing two
motifs (DSGIS and DSAPGS) that negatively regulate NRF2 stability. The Neh7 domain interacts with a
nuclear receptor RXRα. The Neh3, Neh4, and Neh5 domains are known as trans-activation domains of
NRF2. (B) KEAP1 is a 69-kDa protein and contains five domains. The BTB domain is critical for KEAP1
dimerization and recruitment of Cul3-based E3-ligase. The IVR domain has hypercritical cysteine
residues, Cys273 and Cys288 that a e essential for controlling NRF2 activity. Kelch/DGR domain
negatively regulates NRF2 ac ivatio by interacting with onserved carb xyl terminus of Neh2 domain.
BTB, broad complex, tram-track and bric-a-brac; CTR, C-terminal region; Cul3, Cullin3; IVR, intervening
region; KEAP1, kelch-like ECH-associated protein 1; sMaf, musculoaponeurotic fibrosarcoma oncogene;
Neh, NRF2-ECH homologous structure; NRF2, nuclear factor erythroid-2-related factor-2; NTR,
N-terminal region; RXRα,.
KEAP1 is a 69-kDa protein, which belongs to the BTB-Kelch family of proteins [39]. All the members
of this family assemble with Cullin-RING ligases that catalyze general protein ubiquitylation [39].
KEAP1 contains five domains including N-terminal region, the Cullin3 binding broad complex,
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tramtrack and broad complex/tramtrack/bric-a-brac (BTB) homodimerisation domain, the intervening
region (IVR), the Kelch/double glycine repeat (DGR) domain and C-terminal domain [40,41]. The BTB
domain is critical for KEAP1 dimerization and CUL3 assembly requires a BTB protein motif for
ubiquitination and proteasomal degradation of NRF2 [41]. In addition, the BTB domain also contains a
critical cysteine residue (Cys151) that has an important role in the activation of NRF2 [42]. The IVR/BACK
domain contains highly reactive cysteines, namely Cys273 and Cys288 that function as a sensor for NRF2
inducers and are essential for controlling NRF2 activity [43]. Kelch/DGR domain negatively regulates
NRF2 activation by interacting with conserved carboxyl terminus of Neh2 domain [44]. NRF2 controls
antioxidant and cytoprotective genes expression and regulates cellular defense [23]. Under physiological
conditions, NRF2 is kept at low levels in normal tissues by KEAP1-dependent ubiquitination and
proteasomal degradation [29,30]. NRF2 localizes in the cytosol where ETGE and DLG motifs on its
Neh2 domain associate with KEAP1 Kelch domain [45]. A schematic representation of KEAP1 structure
is shown in Figure 1B. KEAP1 acts as an adaptor for NRF2 binding to the KEAP1-CUL3-E3 ubiquitin
ligase complex, an event followed by rapid NRF2 proteasomal degradation [28]. Under oxidative
stress (OS) conditions or in the presence of other stressors including reactive-oxygen species (ROS) or
electrophiles, the activity of KEAP1 is decreased by direct modification of reactive cysteine residues
in the IVR domain. These redox changes induced on KEAP1 thiols alter its structure and prevent
KEAP1-mediated NRF2 ubiquitination [46,47]. Subsequently, NRF2 accumulates in the nucleus where
it induces the expression of its target genes. In the nucleus, NRF2 heterodimerizes with small Maf
proteins through Neh1 domain and promotes the antioxidant responsive elements (AREs)-dependent
expression of cytoprotective genes [46] (see Figure 2). In this regard, over 500 NRF2 target genes
have been so far identified and this number is expected to increase in the next coming future [48,49].
The genetic products of NRF2 activation can be categorized in functional categories covering multiple
cellular processes including phase I, II, III drug/xenobiotic metabolism and detoxification, antioxidant
response and redox homeostasis regulation, iron homeostasis, cellular metabolism, DNA repair,
transcriptional activation, cell proliferation, and apoptosis [46,50]. A selected list of NRF2 target genes
is presented in Table 1.
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Figure 2. NRF2 regulation by KEAP1. Under basal conditions, NRF2 is constantly ubiquitinated
through KEAP1 and degrade in the proteasome in cytosol. Under stress conditions, KEAP1-NRF2
interaction is stopped and free NRF2 translocates into nucleus. Then, NRF2 forms h terodimers with
sMaf and binds to ARE sites within regulatory sites of antioxidant and detoxification genes. ARE,
antioxidant response element; KEAP1, Kelch-like ECH-associated protein1; NRF2, nuclear erythroid-2
like factor-2; Retinoic X receptor alpha sMafs, small musculoaponeurotic fibrosarcoma oncogene family.
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Table 1. Selected list of NRF2 target genes.
Gene Coded Protein Functional Category Biological Role Ref.
GCLC Glutamate-Cysteine LigaseCatalytic Subunit GSH Synthesis & Regeneration GSH Synthesis [51]
GCLM Glutamate-Cysteine LigaseModulatory Subunit GSH Synthesis & Regeneration GSH Synthesis [51]
GSR1 Glutathione Reductase 1 GSH Synthesis & Regeneration GSH Regeneration [51]
SLC7A11 xCT, Light Subunit of Xc-Antiporter GSH Synthesis & Regeneration Cystine Uptake [51]
PHGDH Phosphoglycerate Dehydrogenase GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
PSAT1 Phosphoserine Aminotransferase 1 GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
PSPH Phosphoserine Phosphatase GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
SHMT 1,2 Serine Hydroxymethyltransferase 1,2 GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
GPX1,2,4 Glutathione Peroxidase 1,2,4 ROS & Phase-IIXenobiotic Detoxification ROS Scavenging [21,51]
PRDX1,6 Peroxiredoxin 1,6 ROS & Phase-IIXenobiotic Detoxification ROS Scavenging [52]
TXN1 Thioredoxin 1 Thioredoxin-linked Antioxidant Role Reduction of Sulfenylated-Proteins [51]
TXNRD1 Thioredoxin Reductase-1 Thioredoxin-linked Antioxidant Role Reduction of Thioredoxin [51]
NQO1 NAD(P)H dehydrogenase Quinone 1 ROS & Phase-IXenobiotic Detoxification Reduction of quinones [51,53]
AKR1B1 Aldo-Keto Reductase Family 1Member B1 Phase-I Xenobiotic Detoxification Reduction of aldehydes and ketones [52]
AKR1B10 Aldo-Keto Reductase Family 1Member B10 Phase-I Xenobiotic Detoxification Reduction of aldehydes and ketones [52]
AKR1C1 Aldo-Keto Reductase Family 1Member C1 Phase-I Xenobiotic Detoxification Reduction of aldehydes and ketones [52]
ALDH1A1 Aldehyde Dehydrogenase 1 FamilyMember A1 Phase-I Xenobiotic Detoxification Conversion of aldehydes to carboxylic acids [54,55]
ALDH3A1 Aldehyde Dehydrogenase 3 FamilyMember A1 Phase-I Xenobiotic Detoxification Conversion of aldehydes to carboxylic acids [52]
GSTA 1,2,3,5 Glutathione-S Transferase A1,2,3,5 ROS & Phase-II XenobioticDetoxification Conjugation of Glutathione to electrophiles [51]
GSTM 1,2,3 Glutathione-S Transferase M1,2,3 ROS & Phase-II XenobioticDetoxification Conjugation of Glutathione to electrophiles [51]
UGT1A1,5 UDP Glucuronosyltransferase 1 A1,5 Phase-II Xenobiotic Detoxification Conjugation of Glucuronic acidto electrophiles [52]
ABCC1
ATP Binding Cassette Subfamily C
Member 1/Multidrug resistance
associated protein 1 (MRP1)
Phase-III Xenobiotic Detoxification Transmembrane translocationof xenobiotics [56]
ABCG2 ATP Binding Cassette Subfamily GMember 2 Phase-III Xenobiotic Detoxification Transmembrane xenobiotic transporter [57]
ABCB6 ATP Binding Cassette Subfamily BMember 6
Phase-III Xenobiotic
Detoxification/Heme Synthesis
Transmembrane transport of xenobiotics
and porphyrins [52]
ABCC2 ATP Binding Cassette Subfamily CMember 2 Phase-III Xenobiotic Detoxification Transmembrane transport of xenobiotics [52]
SRXN1 Sulfiredoxin-1 Thioredoxin-linked Antioxidant Role Reduction of Sulfinylated-Peroxiredoxins [51]
G6PD Glucose-6-Phosphate Dehydrogenase NADPH Generation Pentose Phosphate Pathway/Glucose toGlucose 6-Phosphate Conversion [53]
PGD 6-Phosphogluconate Dehydrogenase NADPH Generation
Pentose Phosphate
Pathway/6-Phosphogluconate to Ribulose
5-Phosphate Conversion
[53]
ME1 Malic Enzyme 1 NADPH Generation Malate to Pyruvate Conversion [53]
IDH1 Isocitrate Dehydrogenase 1 NADPH Generation Isocitrate to α-KetoglutarateConversion/TCA Cycle [53]
TKT Transketolase NADPH Generation
Pentose Phosphate Pathway/Conversion of
Xylulose 5-Phosphate and Ribose
5-Phosphate into Glyceraldehyde
3-Phosphate and Sedoheptulose
7-Phosphate
[53]
TALDO1 TransAldolase 1 NADPH Generation
Pentose Phosphate Pathway/Conversion of
Glyceraldehyde 3-Phosphate and
Sedoheptulose 7-Phosphate into Erythrose
4-Phosphate and Fructose 4-Phosphate
[53]
MTHFD2 MethylenetetrahydrofolateDehydrogenase 2 NADPH Generation Serine/Glycine Metabolism [53]
MTHFDL1 MethylenetetrahydrofolateDehydrogenase 1-like NADPH Generation Mitochondrial Tetrahydrofolate Synthesis [58]
HMOX1 Heme Oxygenase 1 Heme & Iron Metabolism Heme to Biliverdin Conversion [51]
FTL Ferritin Light Chain Heme & Iron Metabolism Iron Storage [51]
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2. NRF2 in Cancer Prevention and Therapeutic Implications
2.1. Therapeutic Modulation of NRF2-KEAP1 Pathway for Cancer Prevention
Historically, the NRF2-KEAP1 pathway has been the focus of extensive research aimed at assessing
its potential role in human chronic diseases characterized by alterations of the redox homeostasis such
as diabetes, cardiovascular diseases, neurodegenerative diseases and cancer. Among them, effort have
been made to explore the chemopreventive properties of naturally occurring as well as synthetic
compounds functioning as NRF2 activators or KEAP1 inhibitors in vitro and in vivo. The identification
of the molecular mechanisms underlying NRF2 modulation has driven a renovated interest in the
field of basic and clinical cancer research, fostering a growing number of studies. However, it is now
increasingly recognized that NRF2 can exert oncogenic as well as oncosuppressive functions, so that
the development of effective therapeutic approaches based on NRF2 modulation requires a careful
evaluation of the specific context of its activation including not only the histotype, stage, and genetic
background of a specific tumor but also the therapeutic scheme of administration and the target
population that might benefit from treatment. In the following section, we will describe some of the
most relevant NRF2 activators and their use in cancer treatment.
2.2. Activators of NRF2
Activation of the NRF2 system is complex and can follow canonical and non-canonical pathways.
A difficulty in identifying activators and inhibitors of NRF2 or KEAP1 as modulators of inflammation
and potential protectors against oxidative stress and carcinogenesis, is the dual nature of the
NRF2-KEAP1 protein-protein interaction [26,59–62]. Generally, activation of NRF2 has been viewed as
therapeutic, but recent evidence has suggested that this event can be pro-oncogenic as well, depending
on the context of NRF2 activation [62]. For example, an increased NRF2 activity under “normal”
conditions will lead to improved cell defense against carcinogenesis. By contrast, unrestrained NRF2
activation in a tumorigenic condition, can be protective against stressful conditions and promote
therapy resistance [62]. In cases where NRF2 activation exerts pro-tumoral effects, the therapeutic
applicability of NRF2 inhibitors has been explored. Since the NRF2-KEAP1 pathway can sense
electrophiles as potential stressors, the use of electrophilic drugs to induce its activation would be a
reasonable starting point [41,63]. There is however a substantial concern over potential side effects
associated with the use of electrophilic compounds. This concern has stimulated the development
of other “modulators” of NRF2 activity, considering that the optimal compound would not be a
strong NRF2 activator since the strength of its activation is proportional to the electrophilic effects [64].
More work is needed to determine the potential of NRF2 activators as therapeutic drugs, but first,
the pathways involved must be better elucidated [65].
2.2.1. Electrophilic and Non-Electrophilic NRF2 Activators
Collectively, NRF2-inducers fall into two classes—electrophilic and non-electrophilic [66]—with
the majority of the currently identified inducers belonging to the former class. The mechanism of
action for electrophilic NRF2 activators involves the interaction with the cysteine residues on KEAP1,
resulting in a conformational change that releases NRF2 to its active conformational state. In the
following subsections we will describe both types of molecules, but emphasizing that electrophilic
activators are inherently toxic and when used at sufficiently high doses, will cause electrophilic cellular
damage beyond NRF2 activation [66]. Despite the high risk for side effects, the quest for additional
electrophilic covalent NRF2 activators remains [67] since the advantage of these molecules is due in
part to the extremely high binding energy elicited by covalent binding compared to non-covalent and
the discovery of a low-molecular weight compound able to maintain a high binding affinity is more
likely to occur with covalent activators.
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Electrophilic/Covalent NRF2 Activators
The largest class of chemicals so far identified with the ability to activate NRF2 through
KEAP1 inhibition is represented by triterpenoids [68]. These molecules can bind to KEAP1 and
induce a conformational change that prevents its association with NRF2, promoting its target genes
transactivation. Among the others, 2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid (CDDO) is a
synthetic derivative of the natural triterpenoid oleanolic acid with a very potent (low nanomolar doses)
activating capacity on various NRF2-regulated proteins [66]. CDDO has received much attention due
to its ability to hamper the development of certain tumors [66,69]. Despite KEAP1 contains 15 cysteine
residues susceptible of modification by electrophilic compounds, each electrophile targets its unique
series of residues, a phenomenon referred to as the “cysteine code” [70]. A key cysteine in the binding
of triterpenoids to KEAP1 is C151 [70–72]. However, in order to improve potency, specificity and
reduce potential side effects of CDDO, Methyl ester (CDDO-Me) and imidazole (CDDO-Im) derivatives
have been subsequently developed. Both compounds have shown promising results, as they are
able to activate NRF2 and stimulate ARE-expression at low doses [73,74]. Of note, the ability of the
triterpenoids electrophilic region to react with thiol groups of many proteins and other thiol-containing
molecules underscores the potential side effects associated with their use. For example CCDDO-Im
has been shown to bind to mitochondrial glutathione (GSH), resulting in GSH depletion, increased
oxidative stress, and increased NRF2 activation [75]. Although triterpenoids have therapeutic action at
relatively low concentrations, the risk of serious side effects cannot be excluded.
The compound D3T (3H-1,2-dithiole-3-thione) has been shown to increase the nuclear accumulation
of NRF2, an effect mediated in part by the activation of the ERK 1/2 pathway [76]. ERK 1/2 inhibition
blocked the activation of NRF2 and the effects observed on other ARE-induced gene expression were
similar for oltipraz, another dithiolethione, as well as the natural NRF2-activator, sulforaphane [76].
NRF2 also controls the expression of several isoforms of the multidrug resistance-associated protein
(MDR), a molecular pump that extrudes chemicals outside the cells. Indeed, it has been show that the
administration of oltipraz or butylated hydroxyanisole resulted in a clear upregulation in the MDRs
expression as a consequence of NRF2 activation [77].
Non-Electrophilic/Non-Covalent NRF2 Activators
Recent studies have examined the therapeutic benefits provided by non-covalently bound
non-electrophiles as NRF2 activators, since electrophilic compounds can have side effects and reduce
the activity of certain proteins [78]. Binding studies revealed that cysteine 151 (C151) was an important
target since non-covalent binding to this site promoted cell protection, while in contrast covalent binding
to this residue enhanced cell toxicity [78]. Zhang et al., recently undertook a comprehensive analysis of
nearly 200 chemicals to isolate potential non-electrophilic activators of NRF2. The list was initially
shortened to 86 candidates and subsequently further reduced to only 22 molecules, after the exclusion
of compounds having an electrophilic reactive site. Based on their structures, the chemicals were
placed into one of seven groups consisting of: I—phenothiazine; II—tricyclics; III—trihexyphenidyl;
IV—phenyl pyridine; V—quinolin-8-substituted; VI—tamoxifen substituted; and VII—hexetidine.
The results indicated that each class was able to induce some level of NRF2-mediated increase in
ARE-dependent protein expression [79]. These changes varied between class and protein, but the
systematic approach used to identify biologically active non-electrophilic NRF2 activators opened many
prospects for future development. Another non-covalent small molecule activator of NRF2, RA839,
was shown to activate several pathways related to NRF2 signaling in bone marrow macrophages [80].
Investigations aimed to identify, develop, and then marketing a new non-covalent NRF2 activator
have been hindered by the low affinity and low potency of existing compounds compared to the
covalent agents. However, one potential activator with low toxicity, but still therapeutic utility is
monomethylfumerate (MMF) [59]. Another fumarate-based compound that has demonstrated promise
is dimethyl fumarate (DMF) [81,82]. In addition to screening strategies of existing chemicals based
on their structure and their potential use as non-electrophilic NRF2 activators, other studies are
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underway to find novel compounds. Chemicals that have a naphthalene moiety have shown promise
as non-electrophilic NRF2 activators. Exposure of lung epithelial cells to various naphthalene-based
chemicals led to a marked increase in the expression of several antioxidant enzymes, such as quinone
oxidoreductase (NQO1) and heme oxygenase 1 (HO-1), elicited by NRF2 activation [83]. Few of
these new compounds were of similar potency to sulforaphane, an electrophilic NRF2 activator,
in stimulating the expression of these antioxidant proteins.
2.2.2. Natural Compounds
A 2016 review systematically examined the activation of NRF2 by dietary factors, but also extended
these findings to discuss how diet changes may restrict the nutritional utility of some activators [84].
A natural marine-based compound, honaucin A, obtained from cyanobacteria, has been reported to
have anti-inflammatory properties both in vivo and in vitro. Only recently have investigators begun
to focus on the pathways activated by this compound. Honaucin A forms a covalent bond with
the sulfhydryl groups on KEAP1, resulting in the activation of NRF2 [85]. Many food-based NRF2
activators have been shown to work in multiple organs such as liver [86], lung [87], kidney [88],
brain [89] and gastrointestinal tract [90]. Most of these NRF2 activating compounds are phenol,
polyphenol, or triterpenoid. The use of compounds found in ordinary foods and spices has been an
area of great interest in the last 20–25 years. For example, the spice curcumin, from turmeric and
ginger family, has been reportedly used to treat a variety of disorders. Yet, little work has been done to
fully understand the pathways associated with the therapeutic benefits induced by these chemicals.
Recently, an entire book was dedicated to the beneficial actions of curcumin (The Molecular Targets and
Therapeutic uses of Curcumin in Health and Disease, 2007). Several investigators focused on the molecular
targets of curcumin, including NRF2, on curcumin action, and its uses as a neuroprotective agent
against toxicants inducing oxidative stress but also as an antitumor agent [91–93]. The molecular
action is non-specific with multiple systems and pathways being affected, including the involvement
of NRF2 [94]. Other compounds have been examined with mixed results including silibinin, the active
chemical from the milk thistle, and resveratrol, a biologically active compound from the skins of
various grapes and berries. Both of these molecules have been limited in their usefulness in humans,
due to mostly equivocal findings. Resveratrol has been reported to attenuate oxidative damage in the
liver by increasing the expression and activity of antioxidant enzymes [95,96]. Silibinin has been shown
to decrease metastasis by decreasing the activation of the PI3K-Akt and MAPK (mitogen-activated
protein kinase) pathways in the lung [97], and to enhance apoptosis in colon cancer [98]. From previous
reports, the effects of resveratrol and silibinin on the NRF2 pathway appear to be debatable and might
depend on direct as well as indirect effects.
Foods containing compounds with positive effects on human health are sometimes referred
to as “nutraceuticals.” One chemical class found in cruciferous vegetables is represented by the
isothiocyanates, that include compounds such as sulforaphane, isolated from broccoli, cauliflower,
cabbage, and Brussel sprouts. The role of sulforaphane in ameliorating various health-related disorders
has received a lot of attention, and some of its biological effects were described in 1992 [99]. The utility
of a given compound in a clinical setting is dictated by several properties such as its bioavailability,
potency, and interactions with other drugs. Some aspects of the sulforaphane effects within the body
suggest that there could be some level of clinical utility under certain circumstances [100]. A recent
review describes the multiple pathways affected by sulforaphane administration in reducing tumor
growth, indicating that the NRF2-KEAP1 pathway was a critical targeted [101]. Sulforaphane is
highly electrophilic due to a reactive carbon in the isothiocyanate group that readily reacts with
many nucleophiles containing a sulfur, nitrogen, or oxygen center. By targeting the sulfhydryl
groups of KEAP1, sulforaphane can non-covalently bind to these reactive groups, resulting in NRF2
activation [101]. Sulforaphane can also activate antioxidant response elements (AREs) associated
with NRF2 [102]. Some of the activated redox regulators include glutathione S-transferase, catalase,
glutathione peroxidase, and peroxiredoxins. To improve the functionality of food-based chemicals, it is
Antioxidants 2020, 9, 193 9 of 46
common to use the parent compound as the “backbone” and then to develop modified versions of the
parent endowed with greater efficacy, potency, and possibly also reduced side effects. An example is a
modified sulforaphane, 6-methylsulfinylhexyl isothiocyanate (6-HITC), which was more potent than
sulforaphane in increasing the expression and activity of various AREs in lung epithelial cells [103].
Curiously, not all the effects of sulforaphane are mediated by the NRF2-KEAP1-ARE pathway. Indeed,
sulforaphane can inhibit multiple inflammasomes, sensor systems that activate pro-inflammatory
mediators, as it was recently shown in macrophages and fibroblasts [104]. The mechanisms of action
for sulforaphane and isothiocyanate is complex and may involve multiple mediators. A critical
consideration is also the cell/organ type taken into consideration. Additional research is needed to
help to clarify some of the nutraceutical pathways to better assess their in vivo benefits.
2.3. Potential Use of NRF2 Activators in Cancer Therapy
Whereas new findings indicate that NRF2 plays a dual role in cancer ([26,105,106], the potential
use of NRF2 activators in cancer prevention and therapy needs to be further elucidated. It is widely
accepted that effective chemoprevention should encompass induction of cytoprotective and detoxifying
enzymes. Therefore, the use of compounds able to activate NRF2-KEAP1 pathway and induce
genes involved in antioxidant defense appears to be a possible strategy in both cancer prevention and
therapy [64]. As explained above, NRF2 activators fall into the class of electrophilic and non-electrophilic
compounds [66] and can be of natural origin or semisynthetic/synthetic analogs [64]. As reviewed by
Sanders et al. [107], phenolic and sulfur-containing compounds are the most promising agents in cancer
prevention. Phenolic compounds such as curcumin and resveratrol exert their chemopreventive effect
via activation of NRF2-KEAP1 signaling that induces phase-II detoxifying and antioxidant enzymes
(20638930). Curcumin, a common spice obtained from the rhizomes of Curcuma longa (turmeric),
was shown to induce the expression of antioxidant enzymes such as glutathione S-transferase,
aldose reductase, and HO-1 through NRF2-KEAP1 signaling [108]. Apart from covalent modification
of KEAP1 [109], activation of upstream kinases such as MAPK seems to be an additional mechanism of
NRF2 activation [110,111]. However, the therapeutic success of this compound has been hampered by
its limited bioavailability and rapid metabolism, the poor pharmacokinetic properties [112] and the
lack of conclusive toxicity data [113]. Some studies reporting therapeutic uses of curcumin in various
diseases including cancer are illustrated in Table 2. Resveratrol is a natural compound contained in
edible plants and fruits such as grapes, peanuts, berries, and soy with the reported capacity to increase
the NRF2 levels and promote its nuclear translocation. Resveratrol monomer has been shown to induce
phase-II detoxifying enzymes by activating NRF2 signaling in several human cancer cell lines [114,115]
and to protect from carcinogenicity derived from bioactivated carcinogens [116]. In contrast, the effects
induced by its dimers are poorly understood although the monomer and the dimers have been reported
to act differently in terms of NRF2/ARE induction [117]. Table 2 illustrates some recent in vitro and
in vivo studies reporting the chemotherapeutic use of resveratrol. However, similarly to curcumin,
its poor bioavailability and rapid clearance, made it necessary to develop analogs with improved
pharmacokinetic properties and higher potency [64]. On the other hand, green tea polyphenols such as
(-)-epigallocatechin-3-gallate (EGCG) and (-)-epicatechin-3-gallate (ECG) are known NRF2 activators
showing potent induction of ARE-mediated luciferase activity [118]. EGCG potentiates cellular
defense capacity against chemical carcinogens, UV, and oxidative stress via NRF2-mediated induction
of genes codying for antioxidant or phase-II detoxifying enzymes, modulators of inflammation,
cell growth, apoptosis, cell adhesion etc. [119]. However, it has been shown that EGCG has dual effects
on NRF2-mediated ARE activation depending on its concentration, with higher doses producing
down-regulation and lower doses enhancing HO-1 expression [118,120]. Table 2 summarizes the
results of some studies exploring the potential role of EGCG in the treatment of different pathological
conditions. Other potential chemopreventive agents that exert their properties through NRF2/ARE
pathway are sulfur-containing compounds, such as sulforaphane, contained in cruciferous vegetables
and diallyl sulfide derived from garlic [121,122]. In comparison with curcumin and resveratrol,
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sulforaphane exhibits more potent activation of NRF2 and significantly better bioavailability due
to its lipophilic nature and low molecular weight [123–125]. Preclinical and clinical evaluation of
sulforaphane in breast chemoprevention revealed the presence of its metabolites in the rat mammary
gland after a single oral administration at concentrations known to alter gene expression and also in
human breast tissue after a single dose of broccoli sprout in healthy women undergoing reduction
mammoplasty [126]. These findings provided a strong rationale for evaluating the protective effects
of a broccoli sprout preparation, claiming sulforaphane as a good candidate in the adjuvant therapy
based on natural molecules against several types of cancer [127]. However, some studies indicate
that this compound might exert pro-survival effects in cancer cells [128] and potentially interfere with
the successful application of immunotherapy [129]. Table 2 contains some of the studies conducted
in this field. In a recent review [130] discussing potential combinations of a conventional anticancer
drug (cisplatin or doxorubicin) and a known antioxidant (sulforaphane or curcumin), it has emerged
the necessity of preclinical evidence confirming that the natural compounds can potentiate the
anti-cancer effect of traditional drugs but also reduce the side toxicity in normal tissues. A review
by Robledinos-Anton et al. [65] provides the information on current clinical trials in progress based
on NRF2 activators and their potential clinical use in various chronic disorders, including cancer.
Namely, sulforaphane is in the phase-II clinical trial for the use in treatment of prostate cancer [131]
(NCT01228084) and for breast cancer [132] (NCT00843167), while it has entered the phase-II for
lung cancer prevention (NCT 03232138). Also, curcumin has entered phase-III for the treatment
of prostate cancer [133] (NCT02064673) and resveratrol is in the phase-I for the treatment of colon
cancer [134] (NCT00256334). In an attempt to improve their biological activity, many semisynthetic
and synthetic NRF2 activators have been synthesized and these substances are preferentially used in
clinical practice compared to the natural counterpart. For example, Bardoxolone methyl (CDDO-Me),
a semisynthetic triterpenoid with the ability to protect cells and tissues from oxidative stress by
increasing the NRF2 transcriptional activity, has demonstrated its efficacy as an anticancer drug
in different mouse model [135]. So far, three clinical trials focusing on the use of CDDO-Me in
cancer treatment have been registered. In a phase-I clinical trial investigating the tolerability, safety,
efficacy and pharmacokinetics of CDDO-Me in advanced solid tumors and lymphoid malignancies,
complete response was observed in a patient with mantle cell lymphoma and partial response in
a patient with anaplastic thyroid carcinoma [136]. However, phase-III of the clinical trial designed
to investigate the efficacy of CDDO-Me in patients with stage 4 chronic kidney disease and type 2
diabetes revealed significant increase of heart failure within four weeks of treatment [137]. In any case,
since no evidence of direct cardiotoxicity was found [138,139], trials on this compound are still ongoing.
Another triterpenoid analog, omaveloxolone, has been selected for cancer treatment in three clinical
trials, out of which one is ongoing. Early clinical trials for the treatment of melanoma and NSCLC have
been giving promising results [140]. Dimethyl fumarate (DMF) is a synthetic NRF2 activator which
has already been used for the treatment of multiple sclerosis [141] and is currently tested in a number
of clinical trials, mainly investigating its efficacy in lymphoma, leukemia and melanoma. However,
it should be emphasized that DMF can also exert NRF2-independent effects, suggesting that its activity
might also rely on alternative pathways as evidenced by a recent study [142]. Finally, Oltipraz is an
organosulfur compound which has also entered clinical trials, namely phase-I trial to study its efficacy
in preventing lung cancer in smokers (NCT00006457). However, further clinical trials are needed
to confirm or challenge its possible use as a chemopreventive agent. In conclusion, while the list of
natural, semisynthetic and synthetic NRF2 activators is steadily increasing, it is evident that the drug
development is moving slowly due to the pleiotropic effects of NRF2 activators. More studies on
detailed molecular mechanisms are necessary for their possible application in cancer chemoprevention,
especially in consideration of the possible oncogenic role of NRF2 in cancer cells.
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Table 2. Systematic presentation of studies on possible use of natural Nrf2 activators in therapy with possible mechanisms of action connected to Nrf2
activation pathways.
Natural Products
Type of Study Experimental Model Treatment Doses and Duration Observed Mechanism of Action/Effects Proposed Application in Therapy Ref.
In vivo male Albino ratsWistar strain
200 mg/kg dose of curcumin for four
consecutive days oral administration
• enhanced nuclear translocation and ARE-binding of Nrf2
• curcumin protects against dimethylnitrosamine (DMN)-induced
hepatic injury
chemopreventive agent Zhang J et al., 2018
In vivo male C57BL/6J mice daily treated with curcumin at the dose of 50mg/kg body weight by oral gavage
• mediated nuclear translocation of Nrf2, followed by induction of HO-1
• curcumin intervention dramatically reversed the defects in Nrf2
signaling induced by high fat diet
improving glucose intolerance He HJ et al., 2012
In vivo male Sprague–Dawley rats supplemented with curcumin (1 g/kg diet)for 16 weeks
• increased HO-1 expression was increased along with suppressed
oxidative stress as well as reduced hepatic fat accumulation and
fibrotic changes
attenuating the pathogenesis of
fatty liver induced metabolic
diseases
Oner-Iyidogan Y et al., 2014
In vivo/In vitro
female specific
pathogen-free BALB/c mice
mouse macrophage
RAW264.7 cells
on day 22, the mice were treated with
curcumin (200 mg/kg) 1 h before
ovalbumin challenge.
cells treated with different concentrations (0,
5, 10, 25, and 50 µmol/L) of curcumin for 24 h
or with 50-µmol/L curcumin for different
lengths of time (0, 4, 8, 12 and 24 h)
• Nrf2 and HO-1 levels in lung tissues were significantly increased
• heme oxygenase-1 and nuclear Nrf2 levels were enhanced in dose- and
time-dependent manners in curcumin-treated RAW264.7 cells.
potentially effective drug in asthma
treatment (alleviate airway
inflammation in asthma through
the Nrf2/HO-1 pathway)
Liyun L et al., 2015
In vitro
primary cultures of
cerebellar granule
neurons(CGNs) of rats
pretreated with 5–30 µM curcumin
• mediated neuro-protection against hemin induced damage via Nrf2
dependent HO-1 expression neuroprotective agent
Gonzalez-Reyes S et al.,
2013
In vitro human breast cancer cellline MCF-7
treatment with DMSO (vehicle) or various
concentrations of curcumin for 12, 24 or 48 h
• inhibition of the proliferation of breast cancer cells through
Nrf2-mediated down-regulation of Fen1 expression chemotherapeutic agent Chen B et al., 2014
In vivo female Sprague-Dawley rats
food supplemented with resveratrol
equivalent to 50, 100, or 300 mg/kg
body weight/d
• elevated protein and mRNA expression of hepatic Nrf2, attenuation of
oxidative stress and suppression of inflammatory response mediated
by Nrf2
prevention and intervention of
human hepatocellular carcinoma Bishayee A 2009
In vivo/In vitro
female August Copenhagen
Irish rats non-tumorigenic
human breast epithelial cell
line MCF-10A
resveratrol given as a 50 mg subcutaneous
pellet every other month during 8 months to
animals subcutaneously treated with 3 mg
E2 pellets prepared in cholesterol cells were
treated with E2 (10 and 50 nM) and Res
(50 µM) for up to 48 h
• resveratrol treatment alone or in combination with E2 significantly
upregulated expression of nuclear factor erythroid 2-related factor 2
(NRF2) in mammary tissues; increased expression of NRF2-regulated
genes codying for antioxidant enzymes (NQO1, SOD3 and OGG1)
involved in protection against oxidative DNA damage
• inhibition of suppression of FMO1 and AOX1 genes expression via
regulation of NRF2
a potential chemopreventive agent
in the development of therapeutic
strategies for the prevention of
estrogen-induced breast neoplasia
Singh B et al., 2014
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Table 2. Cont.
Natural Products
Type of Study Experimental Model Treatment Doses and Duration Observed Mechanism of Action/Effects Proposed Application in Therapy Ref.
In vitro MCF-10F and MCF-7 cells
retreated with 0.1 to 30 nmol/L TCDD with
or without 25 µmol/L resveratrol for 72 h
and then incubated with E2 (0.1–10 µmol/L)
for 24 h
• induction of NAD(P)H quinone oxidoreductase 1 (NQO1) in MCF-10F
cells exposed to resveratrol may involve the Nrf2-Keap1-ARE pathway
(dissociation of Nrf2 from Keap 1 and translocation of Nrf2 to the nucleus,
where it binds to the ARE to activate the transcription of NQO1 mRNA)
a potential chemopreventive agent
against estrogen-initiated
breast cancer
Lu F et al., 2008
In vitro
primary rat hepatocytes
were obtained from
Sprague–Dawley male rats
cells were incubated in the presence of
resveratrol for 24 and 48 h ( at concentrations
of 25, 50 and 75 µM)
• increase in the level of Nrf2 and induction of its translocation to the
nucleus, and the increase in the concentration of the coding mRNA
for Nrf2
protection of liver cells from
oxidative stress induced damage
(chemopreventive agents)
Rubiolo JA et al., 2008
In vitro human type II alveolarepithelial cell line, A549
cells were treated with various
concentrations of native EGCG (5, 10, 20, 40,
60, 80 and 100 µM) and nano EGCG (1, 2, 4,
6, 8, 10 and 12 µM) and allowed to grow
for 48 h
• increased expression of Nrf2 and Keap1 in native and nano EGCG
treated A549 cells that could regulate apoptosis chemotherapeutic in lung cancer Velavan B et al., 2018
In vitro bovine aortic endothelialcells (BAECs)
cells treated with various concentrations
of EGCG
• upregulates Nrf2 levels in nuclear extracts and increases
ARE-luciferase activity
therapeutic targets in a variety of
oxidant- and
inflammatory-mediated
vascular diseases
Wu CC et al., 2006
In vivo
male albino Wistar rats;
animal model of
bleomycin-induced
pulmonary fibrosis
intraperitoneally treated with EGCG at a
dosage of 20 mg/kg body weight, once daily
throughout 28 days
• EGCG enhances antioxidant activities and Phase II enzymes involving
Nrf2–Keap1 signaling, with subsequent restraint inflammation during
bleomycin-induced pulmonary fibrosis
• no significant change in the expression of Keap1
treatment of diseases such as
pulmonary fibrosis Sriram N et al., 2008
In vitro
human hepatocytes (HHL5)
and hepatoma
(HepG2) cells
exposed to various concentrations of
sulforaphane for different times with DMSO
(0.1%) as control
• increased nuclear Nrf2 levels and intracellular GSH levels in both cell
lines but with slightly different pattern indicating a potential risk of
chemo-resistance of using sulforaphane for chemoprevention
possible induction of pro-survival
effects in cancer cells Liu P et al., 2019
In vivo male BALB/c mice (6 weeks) 5 µmol/animal sulforaphane plus differentdoses of microcystin-LR
• Nrf2 translocation to the nucleus in mouse livers
• induction of Nrf2 downstream target genes, NQO1 and HO-1, two phase
II enzymes
effective in cytoprotection against
MC-LR-induced hepatotoxicity Sun X. et al., 2011
In vitro adult rat cardiomyocytes exposed to 5µM sulforaphane with orwithout H2O2
• upregulation of Nrf2 by sulforaphane occurs at 1 h of incubation
• increased protein expression of PGC-1α
protective action against oxidative
damage, however, timeline of the
sulforaphane actions needs to
be established
Corssac GB
In vivo male BALB/c mice (6 weeks) 5 µmol/animal sulforaphane plus differentdoses of microcystin-LR
• Nrf2 translocation to the nucleus in mouse livers
• induction of Nrf2 downstream target genes, NQO1 and HO-1, two phase
II enzymes
effective in cytoprotection against
MC-LR-induced hepatotoxicity Sun X et al., 2011
Antioxidants 2020, 9, 193 13 of 46
Table 2. Cont.
Natural Products
Type of Study Experimental Model Treatment Doses and Duration Observed Mechanism of Action/Effects Proposed Application in Therapy Ref.
Electrophilic/Covalent
Triterpenoids
In vitro K562 myeloidleukemia cells
Exposed to 0.05–10 µM CDDO-Me
for 24–48 h
• Down-regulated Na+/K+ ATPase
• Arrested cells in G2/M and S phases
• Increased mitochondria and death receptor-dependent and
ER-mediated apoptosis
• Triggered activation of autophagy
Activated and potentiated the
effects of the apoptosis and
autophagy pathways to kill K562
cancer cells
Wang XY et al., 2017
In vitro and
In vivo
SKOV3, OVCAR3, A2780,
A2780/CP70 and Hey2
ovarian cancer cells
0–50 µM CDDO-Me depending on
cell assays
20 mg/kg CDDO-Me in xenograft model
using nude mice
• Binds to USP7 cells, decreasing MDM2, MDMX and UHRF1
• Suppresses tumor growth in a xenograft model
Targets apoptosis-related
substrates, increasing apoptosis
and reducing growth of ovarian
cancer cells
Qin D et al., 2016
In vitro
MiaPaCa-2 and BxPC-3
cell lines
6 week old Scid/Ner mice
0.625–5µM CDDO-Me in cell culture
CDDO-Me 7.5 mg/kg × 5 days/wk by oral
gavage until day 40 (to treat primary tumor)
or day 100 (to treat residual disease)
• Decreased proliferation and increased apoptosis in K-ras normal and
mutant cells
• Inhibits antiapoptotic pathways
• Inhibited tumor growth in mice
• Increased survival time of mice
Combination of in vitro and in vivo
effects demonstrate that CDDO-Me
will increase apoptosis in
pancreatic ductal adenoma
carcinoma cell lines and improve
the survival of animals
Gao X et al., 2015
In vitro
MDA-MB 435, MDA-MB
231, MDA-MB 468,
BT-549, T47D and MCF-7
breast cancer cells
CDDO-Me 1.5 µM for 4 h
• Induces endoplasmic reticulum vacuolation
• Induces apoptotic pathways
• Increases intracellular calcium and generation of reactive oxygen species
CDDO-Me-induced c-FLIPL
downregulation and relationship
between Ca2+ influx and ROS
generation are keys in controlling
breast cancer growth.
Jeong SA et al., 2015
In vitro HO8910 and SKOV3ovarian cancer cells
CDDO-Me concentration range of 0–100 µM
5 µM CDDO-Me in assays requiring a
single concentration
• Upregulates Hsp70
• Degrades Hsp90-associated protein—ErbB2 and Akt
• CDDO-Me reacts with nucleophiles on Hsp90 to form Michael adducts
May provide added insight to
CDDO-Me action, with Hsp90 as a
novel target
Qin DJ et al., 2015
In vivo
C57BL/6 WT mice
LSL-KrasG12D/+;
Pdx-1-Cre (KC) mice
Polyoma-middle T
(PyMT) mice
CDDO-Im (100 mg/kg diet) fed 2 days prior
to LPS injections
• Reduced the lethal effects of LPS injection in mutant mice
• Increased migration of CD45+ cells
• Increased percentage of Gr1+ myeloid-derived suppressor cells
• CDDO-Im decreased IL-6, CCL-2, VEGF, and G-CSF in mutant mice
Postulating the use of CDDO-Im as
prophylaxes in the development of
pancreatic cancer within
susceptible populations. This is
due to the reduction in
proinflammatory mediators.
Leal As et al., 2016
In vitro Human Jurkat E6-1 cells CDDO-Im 1 nM and 10 nM for 30 min priorto activation with anti-CD3/anti-CD28
• Inhibited production of IL-2
• Suppression of CD25 in Nrf2-dependent manner with no effect on CD69
Nrf2 activation by CDDO-Im
reduces IL-2 secretion and CD25
expression suggesting a role in
potential anticancer therapy.
Zagorski JW et al., 2017
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Table 2. Cont.
Natural Products
Type of Study Experimental Model Treatment Doses and Duration Observed Mechanism of Action/Effects Proposed Application in Therapy Ref.
Dithiolethiones ·
In vitro Mouse carcinomaHepa-1c1c7 cells
Oltipraz 5–60 µM
anetholedithione (ADT) 3–15 µM
1,2-dithiole-3-thione (D3T) 1–5 µM
• Dithiolethiones are reduced in Hepa-1c1c7 cells leading to generation of
superoxide radicals
• Superoxide dismutates to form hydrogen peroxide promoting
translocation of Nrf2 to nucleus
• Translocated Nrf2 results in the upregulation of various Phase II
enzyme expression.
Use of D3T and members of this
family may be able to modify
KEAP-1 activity and upregulate the
expression of Phase II enzymes
Holland R et al., 2009
In vivo Male Fischer 344 (100 g)
D3T administered by oral gavage 0.5
mmol/kg (in distilled water with 1%
Cremaphor, and 25% glycerol
• Increased heme oxygenase (HO-1) activity
• Increased expression of HO-1
• Increased levels of ferritin
Very early paper describing the
potential utility of Dithiolethiones,
like D3T, may offer protection
against pro-carcinogenic
compounds that increase
oxidative stress
Primiano T et al., 2006
In vitro HT29 colonadenocarcinoma cells
30µM D3T in DMSO vehicle (less than 0.1%
final DMSO concentration)
• Increased expression and activity of multiple reductases—Thioredoxin
reductase 1, prostaglandin reductase 1, NAD(P)Quinone
oxidoreductase 1
• Potentiation of hydroxymethylacylfulvene action in alkylating DNA
D3T was a much stronger inducer
of reductases compared to selenite
and increased potency of the
anticancer drug,
hydroxymethylacylfulvene
Erzinger MM et al., 2014
In vivo Male Fisher 344 rats(90–100 g)
Oral gavage of DST at 0.03 to 0.3 mmol/kg
body wt at 3 days/week for 3 weeks
Also 0.1 mmol/kg for measuring hepatic
protein expression
• Reduced the pre-cancer potency of aflatoxin B by inhibiting the
expression of glutathione S-transferase-placental isoform
• Blocked aflatoxin-mediated increase in
• Induced multiple hepatic genes associated with detoxifying
aflatoxin—including glutathione
• S-transferase A5 (GSTA5) and AFB1 aldehyde reductase
D3T is more potent than older
Dithiolethiones like oltipraz and
could be a probe for measuring
anticancer potencies of this
drug class
Roebuck BD et al., 2003
In vitro HepG2 hepatic and LS180colon cells
S-diclofenac and S-sulindac in range of
0–100 µM
• Inhibited activity and expression of CYP1A1, 1B1 and 1A2
• Regulates aryl hydrocarbon receptor pathway
• Blocked binding of aryl hydrocarbon to the responsive element
• Increased expression of anticancer enzymes, glutathione S transferase,
glutamate cysteine ligase, and glutathione reductase
The NSAIDs with the
dithiolethione group, S-diclofenac
and S-sulindac, may function as
effective anticancer agents
Bass SE et al., 2009
In vitro HT29 and HCT116 colonadenocarcinoma
100 µM Oltipraz with 0.2% MeSO as a
solvent control
• Induction of p65, IκB kinase α (IKKα), IκB kinase β (IKKβ), and
NF-κB-inducing kinase (NIK)
• IκBα phosphorylation was also induce
• Induction of protein binding to a consensus NF-κB element
• Transcriptional activation of QR was decreased
• Both MEKK3 and NIK exert effects on IKKα/β activation via
different pathways
This is a novel pathway involved in
QR gene regulation and may
provide insight to the actions of
oltipraz as an anticancer agent
Nho CW et al., 2004
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Table 2. Cont.
Natural Products
Type of Study Experimental Model Treatment Doses and Duration Observed Mechanism of Action/Effects Proposed Application in Therapy Ref.
Non-Electrophilic/Non-Covalent
In vivo and
in vitro
Male C57/Bl6 mice (22 g)
and bone marrow-derived
mouse macrophage cells
RA839 was dissolved in a vehicle of 95%
(v/v) hydroxyethyl cellulose (0.5% (w/v))/5%
(v/v) solutol—injected IP at 30 mg/kg.
General RA839 interactions measured at a
concentration of 10 µM
• Binds to KELCH domain with affinity of 6 µM
• Blocks Nrf2-Keap-1 protein-protein interaction
• Modified activity of multiple genes in mouse macrophage cells
• Reduced the induction of nitric oxide release and inducible nitric oxide
synthase activity
• Induced Nrf2 gene expression in mouse liver
RA839 may be a useful tool in
developing anticancer drugs that
target the prevention of Nrf2-Keap1
protein interaction.
Winkel AF et al., 2015
In vitro THP-1 cells Cells were exposed to TAT14 using aconcentration range of 0–75 µM
• Activates heme oxygenase 1 expression and activity
• Did not alter Nrf2 mRNA expression
• Reduced LPS-induced TNF expression
The 14-mer TAT fragment interacts
with Keap1, preventing Nrf2-Keap1
association, allowing Nrf2 to
activate mediators downstream
Steel R et al., 2012
In vitro HepG2 hepatic and U2OSbone cell lines
ML334 and its isomers in a concentration
range of 0–100 µM
• Binds with high affinity to KEAP1
• Strong inducer of ARE activity in both hepatic and bone cell lines
First description of ML334 as a
potent inhibitor of Nrf2-Keap1
interaction. Highly potent.
Magesh HL et al., 2013
In vitro
Immortalized baby mouse
kidney epithelial cells
(iBMK) and MDA-MB-231
breast cancer cells
Geopyxin F and other “geopyxin” isomers
were used in a concentration range of
0–70 µM depending on assay
• Geopyxin F was the most potent of Geopyxin compounds at inducing
Nrf2 activity
• Geopyxin F displayed almost not toxicity/lethality in MDA-MB-231 cells
• Geopyxin F increased autophagosome formation in iBMK cells
• Geopyxin F prevents ubiquitination and stabilizes Nrf2
(KEAP1-dependent)—but is independent of interactions at the Cys151
in KEAP1
Geopyxin F, demonstrated a higher
level of protection compared to
electrophilic Nrf2 activators.
Heightened potency suggests that
Geopyxin F may be a useful
anticancer compound.
Liu P et al., 2019
In vitro MCF-7 breast cancer cells
Multiple drugs were used as “off-label”
activators of Nrf2
Astemizole 8 µM
Tamoxifen 1 µM
Trifluoperazine 10 µM
• Astemizole, Tamoxifen and Trifluoperazine increased expression of the
NQO1, HO-1, and GCLM genes
• After 24 h, the stimulated gene expression to basal was highest in
Astemizole compared to sulforaphane
• The genes for the detoxifying enzymes—NAD(P)H quinone
oxidoreductase 1 (NQO1), heme oxygenase 1 (HO1) where most
sensitive to upregulation
After large-scale screening, select
drugs were chosen based on their
ability to activate Nrf2. This shows
that ‘off-label’ mechanisms may
have benefit as anticancer drugs.
Astemizole was the best candidate.
Zhang QY et al., 2017
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3. NRF2 in Cancer Promotion and Therapeutic Implications
3.1. Pro-Oncogenic Roles of the NRF2-KEAP1 Pathway
Given that NRF2 promotes cell survival in stress conditions [143], it is consequently accepted that
enhanced NRF2 activity can be tumor promoting through several molecular mechanisms that protect
cancer cells (Figure 3). This is a way by which cancer cells gain advantages over the normal cells, such as
enhanced tumorigenic capacity, resistance to therapeutic agents and increased antioxidant activity
leading to “NRF2 addiction” that turns this cellular guardian into a cancer driver [3]. Several important
studies suggest that common oncogenes, such as KRAS, BRAF, and MYC, can directly promote the
transcription of NRF2 through the modulation of signaling pathways such as the Raf-MEK-ERK-Jun
cascade [14,53,144]. This overactivation of NRF2 leads to enhanced cytoprotective activity and,
remarkably, to a decrease in ROS levels. Thus, probably oncogenes partly boost cancer development
through an NRF2-dependent creation of a more favorable intracellular milieu for tumor cells selection.
Constitutive activation of NRF2 in cancer promotion and the mechanisms that lead to this condition, are
under debate. Many researchers have spotted cancer-associated mutations that activate NRF2 [145–150].
Mutations in NRF2 that lead to gain-of-function can be detected mainly in squamous cell carcinomas
of the oesophagus, lung, larynx, and skin [151]. Additionally, aberrant NRF2 activation in cancer cells
leads to remarkably increased expression of TKT and G6PD metabolic enzymes that contribute to
metabolic reprogramming and cell proliferation [53]. Other evidence indicates that deficiencies in
autophagy, and therefore activation of NRF2 and overexpression of p62, might promote induction of
hepatic tumors [152]. As for the hormone related cancers, it has been reported that specific hormones
lead to significant upregulation of NRF2 in ovarian cancer cell lines [153]. Epigenetic modifications
seem to control the expression of KEAP1/NRF2 system and therefore it is important to investigate this
type of regulation in cancer [154–156]. Another major topic is the enhancement of chemoresistance
and radioresistance in cancer cells. For example, overactivation of NRF2 by pretreatment with a
synthetic antioxidant was found to increase the survival of neuroblastoma cells treated with three
chemotherapeutic drugs [157]. Finally, it has been demonstrated that radiation therapy leads to
generation of ROS and depletion of GSH, frequently causing enhanced synthesis of antioxidant
enzymes such as GCLC, HO-1 and TXRD1 by NRF2 activation, as reported in a recent study on
prostate cancer cells [158]. One question that needs to be addressed, however, is whether the increase
in NRF2 levels is a key step in cancer development. The existing body of evidence suggests that KRAS
and BRAF increase the levels of JUN that in turn binds to well-known transcription starting sites of
NRF2 promoting its induction. This finding suggests that some of these effects can be direct [14].
Moreover, many findings indicate that ROS levels should be suppressed in order to prevent cancer
development due to their involvement in promoting and sustaining carcinogenesis [62,159]. It has
also been proposed that utilizing drugs that boost ROS production can be an effective way of killing
cancer cells [160]. Concomitantly, it is of utmost importance to determine the specific pathways and the
equilibrium between ROS and NRF2 so as to elucidate the paradoxical role of KEAP1/NRF2 pathway
in cancer. A schematic illustration of the pro-oncogenic functions of NRF2 is presented in Figure 3.
In the following sections we will describe more in detail some of the most relevant hallmarks of cancer
cells that are regulated by NRF2 activation.
3.1.1. Sustained Proliferation
The KEAP1-NRF2 pathway is a vital defense system against oxidative and electrophilic
stress in normal cells as well as cancer cells that use it to foster their unrestricted growth [3].
Temporary activation of NRF2 is critical for the survival of non-cancerous cells and protection
against carcinogenesis [161]. However, constant activation of this pathway is detrimental especially
in a cancerous context since NRF2 exerts a pro-tumoral function by supporting sustained cancer
cells proliferation through various mechanisms [3]. Studies with lung cancer, pancreatic cancer,
and hepatocellular carcinoma cell lines showed that NRF2-KEAP1 status directly affects their
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proliferation rates since NRF2-negative cells proliferate slower, while KEAP1-deleted cells proliferate
faster than their wild type counterparts [162–164]. Moreover, NRF2 was seen to promote oncogenic
K-RasG12D-initiated tumor formation and proliferation of pancreatic and lung cancers in vivo and
K-RasG12D, BRAF V619E, and MYC-induced NRF2 transcription [14,165]. The role of NRF2 on
cancer cell proliferation relies on the functions of the genes regulated by its own transcriptional
activation [166]. The genes that regulate the proliferative capacity of normal cells such as NOTCH1,
NPNT, BMPR1A, IGF1, ITGB2, PDGFC, VEGFC, and JAG1 are known NRF2 targets and contribute
to cancer cells survival [51]. On top of these genes, NRF2 also regulates the expression of genes
needed to fulfill the constant demand of protein synthesis of cancer cells such as PHGDH, PSAT1,
PSPH, SHMT1, and SHMT2 by activating the critical effector ATF4 [51,167]. Apart from increased
protein synthesis, highly proliferating cells also require energy and small building blocks to synthesize
other macromolecules [168]. In this context, NRF2 regulates the expression of enzymes such as
G6PD,TKT, TALDO1, PPAT, MTHFD2, IDH1, and ME1 in lung cancer cells [53]. Furthermore, NRF2 is
involved in the regulation of genes required for the synthesis of GSH (reduced glutathione) and
NADPH (reduced Nicotinamide adenine dinucleotide phosphate), two crucial molecules for cell
proliferation [169]. Besides glucose metabolism, NRF2 also regulates genes involved in fatty acid
and lipid metabolism [170]. There is also evidence of indirect involvement of NRF2 on cancer cell
proliferation by regulating several non- coding microRNAs, such as mir-1 and miR-206. These miRNAs
normally inhibit TKDT and G6PD genes, and their repression by HDAC4 through NRF2 supports
cancer cells growth [171]. In summary, it is clear that the increased activation of NRF2 allows
cancer cells to proliferate faster as a consequence of cytoprotective genes induction and metabolic
reprogramming [168]. Due to the advantages granted by its activation, the cancer cells acquire a
phenotype of “NRF2 addiction” which is characterized by aberrant NRF2 accumulation in both murine
and human cancers [3]. Thus, the impairment of NRF2 pathway is expected to repress tumor growth,
and this is the basis of developing drugs against NRF2 in a context-dependent manner for the targeted
therapy of various cancers [172].
3.1.2. Angiogenesis Induction
The presence of constantly growing cells in tumor microenvironment causes depletion of oxygen
and nutrients and creates an urgent need for a continuous supply of blood flow to fulfill the increased
metabolic demand and to remove wastes and carbon dioxide [173]. Hypoxic tumor microenvironment
induces the expression of VEGF through the transcription factor HIF-1a for the generation of new blood
vessels, a process known as angiogenesis [174]. Other than VEGF, PDGF, angiopoietin, angiogenin and
extracellular matrix elements participate also to the regulation of angiogenesis [175]. NRF2 modulates
angiogenesis by itself and through its targeted genes [176]. Depletion of NRF2 decreases the levels of
HIF-1a, which in turn causes reduction of blood vessels formation through regulation of VEGF in rat
gastric epithelial cells, glioblastoma and colon cancer xenograft models [177–179]. In recent studies,
it was reported that regulation of VEGF by NRF2 also depends on PI3K/AKT/mTOR pathways in
endothelial cells [180,181]. These data suggest that both proliferative and pro-angiogenic effects of
PI3K/AKT/mTOR and NRF2 pathways cooperate in favor of cancer cells. NRF2 also indirectly regulates
HIF-1a levels by preventing its proteasomal degradation by the aid of NQO1 [161,182]. Angiogenesis is
also regulated by common effectors of NRF2 and HIF1a including HO-1, platelet-derived growth factor
(PDGFC), and fibroblast growth factor (FGF2) [183–185]. Among these genes, HMOX1 was shown to
promote angiogenesis in various cancers such as glioma, pancreatic cancer, and melanoma [176,186].
Intriguingly, there is an interplay between NRF2 and HIF1-a pathways since VEGF can in turn activate
NRF2 via ERK1/2 signaling [187]. Another evidence supporting the crosstalk between NRF2 and
HIF-1a pathway comes from the recent data showing that PIM kinases, upstream regulators of HIF-1a,
promote NRF2 nuclear accumulation in response to hypoxia and in normoxia, leading to increased
cancer cells survival in the hypoxic tumor microenvironment [188]. In conclusion, the induction of
angiogenesis can be counted as one of the critical roles of NRF2 in promoting tumorigenesis.
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consumption in black. The abbreviations are: ACC1, Acetyl-CoA Carboxylase 1; ACL, ATP-Citrate
Lyase; CPT, Carnitine PalmitoylTransferase; ELOVL, fatty acid Elongase; FADS, Fatty Acid Desaturase;
FASN, Fatty Acid Synthase; G6PD, Glucose-6-Phosphate Dehydrogenase; GCLC, Glutamate-Cysteine
Ligase, Catalytic subunit; GCLM, Glutamate-Cysteine Ligase, Modifier subunit; GLS, Glutaminase;
GS, Glutathione Synthetase; IDH1, Isocitrate Dehydrogenase 1; ME1, Malic Enzyme 1; MTHFDL,
MethyleneTetraHydroFolate Dehydrogenase 2; PGD, 6-phosphogluconate dehydrogenase; PHGDH,
phosphoglycerate dehydrogenase; PPAT, phosphoribosyl pyrophosphate amidotransferase; PSAT1,
phosphoserine aminotransferase; PSPH, phosphoserine phosphatase; SCD1, stearoyl CoA desaturase;
SHMT 1-2, serine hydroxymethyltransferase 1 and 2; TALDO, transaldolase; TKT, transketolase; TXN,
thioredoxin; UCP3, uncoupling protein 3; xCT, glutamate/cystine antiporter. G6P, glucose-6-phosphate;
F6P, fructose-6-phosphate; F1,6BP, fructose-1,6-bisphosphate; GA3P, glyceraldehyde-3-phosphate; 3PG,
3-phosphoglycerate; PEP, phosphoenol pyruvate. PPP: 6PGL, 6-phosphoglucono-d-lactone; 6PG,
6-phosphogluconate. PRPP, 5-phospho-D-ribosyl-1 pyrophosphate; IMP, inosine monophosphate.
Ser/Gly synthesis: 3PHP, 3 phosphohydroxypyruvate; 3PSer, 3-phosphoserine; THF, tetrahydrofolate;
MTHF, methylenetetrahydrofolate; 5,10-FTHF, 5,10-methenyl-tetrahydrofolate. b-Oxidation: Acyl-CoA,
acyl-coenzyme A; Ac-CoA, acetyl-coenzyme A. FA, fatty acid. GSH, glutathione, reduced.
3.1.3. Resistance to Apoptosis
NRF2 protects healthy cells from endogenous ROS and is a critical regulator of drug metabolism
and antioxidant enzymes [21,46]. NRF2 leads to diminished apoptosis and increased drug
resistance [189,190]. Inhibition of NRF2 signaling enhances apoptosis in response to oxidative
insults [105,191]. Conversely, activation of NRF2 by chemopreventive agents decreases the number of
apoptotic cells [192–194]. There are many studies showing elevated expression of NRF2 in various
types of tumors such as non-small cells lung cancer (NSCLC), esophageal squamous cell cancer
(ESCC), gastric cancer (GC), head and neck cancer (HNC), breast cancer (BC), ovarian cancer (OC),
and endometrial cancer (EC) [46]. NRF2 signaling is activated during malignant transformation in
response to radiotherapy/chemotherapy and it protects cancer cells from cell death by upregulating
a number of ROS-scavenging enzymes that counterbalance the increased ROS production [195].
Moreover, NRF2 allows the cancer cells to escape death by cooperating with other pathways playing
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a role in apoptosis regulation. For instance, the tumor suppressor p53 inhibits NRF2 signaling by
down regulating the expression of NRF2 target genes such as x-CT, NQO1, and GST1 and triggers
cell cycle arrest and apoptosis [196–198]. Under mild cellular stress conditions, the p21 protein,
a major p53 target, binds to the DLG motif and prevents KEAP1-mediated NRF2 proteasomal
degradation, activating the antioxidant response [199]. Additionally, other studies have shown that
mutant p53 leads to constitutive NRF2 activation without affecting its expression and enhances
cancer cells survival [200,201]. Glutathione-S-transferase pi 1 (GSTP1) is one of the downstream
targets of NRF2 that inhibits proapoptotic c-Jun N-terminal kinases (JNKs) activity and promotes
cell survival [202]. Importantly, p62 is another NRF2 target, which mediates autophagic degradation
of KEAP1 and therefore enhances NRF2 stability, suppressing apoptosis [203]. Finally, Bcl-2 is a
well-known anti-apoptotic protein that promotes increased cell survival and drug resistance [204,205].
NRF2 upregulates Bcl-2 expression through direct binding of the ARE sequence on its promoter,
which induces oncogenesis [206]. All of these studies indicate that NRF2 plays a critical role in tumor
survival and drug resistance through the inhibition of apoptosis via different pathways.
3.1.4. NRF2 Signaling in Metastasis
Epithelial to mesenchymal transition (EMT) is a biological process that contributes to cancer
metastasis and tissue invasion [207,208]. During EMT, the expression of E-cadherin and other
epithelial phenotype-related genes is repressed while conversely the expression of mesenchymal
phenotype-related genes such as vimentin and N-cadherin is activated by EMT regulators (Snail,
Slug, Twist, Zeb, etc.) [209,210]. As a result, epithelial cells turn into mesenchymal cells by losing
their cell–cell adhesion and cell polarity features and acquiring invasive and metastatic properties.
Constitutively active NRF2 has been shown in human cancers with higher metastatic capacity [211].
In addition, the correlation of NRF2 expression with cancer progression, metastasis and drug resistance
has been reported in many different studies [14,15,46,212]. NRF2 promotes EMT and invasion in
pancreatic adenosquamous carcinoma cells through downregulation of E-cadherin gene expression [213].
NRF2 knockdown (KD) increases E-cadherin expression and downregulates N-cadherin and matrix
metalloproteinase 2 and 9 (MMP2, MMP9) genes expression and reduces migration and invasion
capacity of NSCLC cells [214]. Overexpression of NRF2 in BC cells promotes cell proliferation and
metastasis via activating NRF2 target gene NOTCH1 that in turn induces the expression of genes
promoting EMT [215]. NRF2 also positively regulates theRhoA gene, which is a critical factor for growth
and metastasis, while NRF2 down regulation inhibits proliferation of BC cells [216]. Furthermore,
recent findings demonstrate that NRF2 expression is upregulated in human hepatocellular carcinoma
(HCC) and that NRF2 promotes proliferation and tumor metastasis by regulating Bcl-xL and MMP-9
genes expression [164]. In contrast, other studies have shown that low expression levels of NRF2 also
play a critical role in cancer progression and metastasis formation. In human prostate cancers (PC),
NRF2 and its target genes were shown to be significantly decreased during the metastatic process [217].
Additionally, it has also been reported that repression of NRF2 in HCC cell lines increased cell metastasis
and invasiveness via TGF-β/Smad-dependent signaling [218]. Moreover, NRF2 deregulation was also
shown in other cancers like OC, lung adenocarcinoma (LUAD), human head and neck squamous
cell carcinoma (HNSCC) [217,219]. Taken together, all these studies demonstrate that NRF2 has both
metastatic and anti-metastatic activity in different types of tumor and stages of cancer progression.
It seems like cancer cells utilize both upregulation and downregulation of NRF2 signaling for their
advantages. To interfere with cancer metastasis, it will be necessary to fully elucidate the role of NRF2
expression in the metastatic microenvironment.
3.1.5. Metabolic Reprogramming by NRF2: NADPH Links Tumor Growth and Redox Balance
It is well known that cancer cells reprogram their central metabolism to meet the energetic
needs imposed by their uncontrolled growth. Initial studies mainly focused on the Warburg
effect, while subsequent work also investigated changes in the one-carbon and fatty acids
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metabolism, pentose phosphate pathway (PPP), tricarboxylic acid cycle (TCA) and glutamine
catabolism [173,220,221]. In general, NRF2 can control multiple metabolic routes by two different
mechanisms, similarly to other oncogenes (e.g., MYC or KRAS): the first involves direct transactivation
of key metabolic enzymes [222], while the second relies on the modulation of proteins controlling
other signaling pathways such as PPARγ [223], Notch [215,224], AHR [225,226] and PI3K/AKT [53].
It is known that alterations of tumor metabolism are often paralleled by an increased antioxidant
capacity, which is also part of the adaptive response mounted by cancer cells to face adverse
conditions, including OS [173,227–230]. With this respect, certain metabolic reactions can play a dual
role, providing intermediates for biosynthetic processes or essential cofactors used to modulate the
intracellular redox balance [231–235]. Among them, NADPH represents a key player in supporting
anabolic reactions and ROS-scavenging antioxidant systems. As first, NADPH is essential for
the regulation of the glutathione/glutaredoxins (GRXs) system, that regenerates the reduced form
of glutathione (GSH) once it is oxidized (GSSG) [236]. Secondly, NADPH is a key cofactor for
the glutathione peroxidases (GPXs) that scavenge hydrogen peroxide or potentially harmful alkyl
hydroperoxides. Lastly, NADPH is indispensable for the thioredoxin reductases (TRXRs), a class of
enzymes that restore the reduced form of thioredoxins (TRXs) and indirectly contribute to the regulation
of thiol groups in redox-sensitive proteins [237,238]. Importantly, NRF2 can enhance the expression of
genes codying for NADPH-producing enzymes such as G6PD (Glucose-6-Phosphate Dehydrogenase)
and PGD (Phospho Gluconate Dehydrogenase), or enzymes that regenerate glycolytic intermediates
that can be diverted into the oxidative PPP branch, such as TKT (Transketolase) and TALDO1
(Transaldolase-1) [53,182,215,239]. Mechanistically, either direct or indirect genes transactivation
can occur, depending on the genetic and biological context of NRF2 activation. Indeed, by using
H1437, A549 NSCLC and DU145 PC cells, Singh et al., reported that genetic induction of PPP genes
was mediated by NRF2-dependent repression of miR-1 and miR-206, two negative regulators of
G6PD, PGD and TKT expression, through yet unknown epigenetic mechanisms involving the histone
deacetylase HDAC4 [240]. Also miR-1 inhibition was found to underlie NRF2-mediated upregulation
of G6PD in HCC cells, an event that positively correlated with grading, metastasis number and
poor prognosis in HCC patients [241]. Instead, a direct induction of G6PD, PGD, TKT, TALDO1 and
other NADPH-producing enzymes was reported in A549 NSCLC cells with sustained PI3K/AKT
pathway activation [53], in agreement with previous ChIP-seq studies [48,182,242]. Also, Xu et al.,
demonstrated that NRF2 can bind to the AREs within intron 1 and 4 of the TKT gene, inducing its
expression in HCC cells (SMMC and MHCC97/L) [239]. Consistently, the presence of functional
NRF2 binding sites within the AREs of the TKT promoter was also reported in MEFs and A549
NSCLC cells, suggesting a direct transactivation mechanism [240]. Also, other data indicate that
NRF2 overexpression or KEAP1 KD can upregulate the mRNA and protein levels of G6PD and
TKT, enhancing tumor proliferation, migration and invasion of MCF7 and MDA-MB-231 BC cells
by promoting EMT through G6PD/HIF-1α activation of Notch1 signaling, while NRF2 silencing or
KEAP1 overexpression reverted these changes [215]. Interestingly, some studies suggest that NRF2 can
control the expression of NADPH-producing enzymes involved in one-carbon metabolism such as
MTHFD2 (Methylenetetrahydrofolate Dehydrogenase 2) or in the TCA cycle, such as IDH1 (Isocitrate
Dehydrogenase 1) and ME1 (Malic enzyme 1) [53,239,243], while others indicate that NRF2-dependent
induction of the folate-cycle enzyme MTHFDL1 (Methylenetetrahydrofolate Dehydrogenase 1-like)
can increase the NADPH levels in HCC cells, supporting proliferation and redox homeostasis [58].
3.1.6. NRF2 Regulates Metabolic Processes Leading to GSH Synthesis and TCA Cycle Anaplerosis
In line of principle NRF2 can also regulate the redox balance of cancer cells via transcriptional
induction of metabolic enzymes or membrane channels that control the availability of cysteine,
glutamate and glycine, essential precursors in the GSH synthesis. In this regard, NRF2 was
shown to enhance the expression of key enzymes for serine/glycine biosynthesis such as PHGDH
(Phosphoglycerate Dehydrogenase), PSAT1 (Phosphoserine Aminotransferase 1), PSPH (Phosphoserine
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Phosphatase) and SHMT1-2 (Serine Hydroxymethyltransferase 1-2) in a panel of NSCLC cells [167].
Also, a recent work underlined the importance of the NRF2-ATF4 pathway in the regulation of
aminoacid metabolism in cancer. Indeed, NRF2 was seen to enhance the ATF4 transcriptional activity
in autophagy-deficient HCT116 CRC cells, promoting the expression of genes (SLC6A9, SLC36A4,
SLC38A1, and SLC38A3) codying for AATs (aminoacid transporters) involved in the uptake of glycine
and glutamine. Notably, AATs inhibition sensitized autophagy-deficient CRC cells but not wild-type
cells to apoptosis induced by glutamine withdrawal [244]. Other work has focused on xCT, an antiporter
that couples the eﬄux of glutamate with the uptake of cystine (CySS), that is intracellularly reduced to
cysteine (2x Cys) by GSH, TRX1 or TRP14 [245–249]. For example, Habib et al., showed that in MCF7
BC cells exposed to OS, an enhanced NRF2 nuclear translocation was responsible for the SLC7A11
(solute carrier family 7 member 11) gene upregulation, leading to an increase in the xCT mRNA and
protein levels and marked glutamate release. Of note, these changes were phenocopied by NRF2
overexpression or KEAP1 KD and reverted by its overexpression [250]. In a later study, NRF2 and
SLC7A11 expression was found to be positively correlated across 947 cancer cell lines from the CCLE
dataset [251], especially within 59 different BC cell lines. Here, NRF2 KD markedly decreased SLC7A11
expression and glutamate extrusion in Hs578T and MDA-MB-231 BC cells, improving cell viability
upon glucose depletion while in the same conditions NRF2 activation by DMF impaired cell viability.
Thus, despite the enhanced activation of the NRF2-xCT axis might efficiently preserve the redox
homeostasis of BC cells under OS, it might also decrease their metabolic flexibility, unveiling a specific
vulnerability that can be therapeutically exploited [252]. In a study on human melanoma cells with
constitutive BRAF activation (BRAFV600E), Khamari et al., explored potential metabolic changes
promoting resistance (A375RIV1 cells) or sensitivity (A375-v cells) to the BRAF inhibitor Vemurafenib,
by using an in vivo long-term treated xenograft mouse model. Here, A375RIV1 cells exhibited a
strong activation of the NRF2 signaling, followed by an increased expression of genes involved in ROS
scavenging (i.e., GPX1, GPX2), GSH synthesis (i.e., GCLM, and xCT) and NADPH-generation (i.e., TKT,
TALDO1), compared to the A375-v counterpart. Of note, NRF2 KD by siRNA decreased the protein
content of its target genes in A375RIV1 cells, partly reversing their resistance to Vemurafenib [253].
Thus, the xCT system is key regulator of cancer cells redox balance, while its inactivation might
sensitize malignant cells to OS inducers. Of note, xCT overexpression is expected to promote glutamine
catabolism to support TCA cycle anaplerosis or GSH synthesis [254]. In this respect, a recent study
from Sayin et al., reported that LOF mutations of the KEAP1 gene can mediate glutamine addiction in
both mouse (KPK) and human KRAS-driven LUAD cell lines. Here, NRF2 increased activation led to
enhanced xCT/SLC7A11 expression, causing an imbalance in the TCA cycle and sensitization of KPK
cells to pharmacologic or metabolic glutamine depletion. Importantly, the glutaminase inhibitor CB-839,
impaired cell growth in a panel of tumor cells including melanoma, colon, renal, bone, squamous and
urinary-tract cancers with KEAP1 LOF mutations while the use of KI696, a small-molecule activator
of NRF2, conversely sensitized KEAP1 WT cancer cells previously refractory to CB-839 [255]. Thus,
oncogenic alterations in the NRF2-KEAP1 axis can induce defects in central carbon metabolism of
cancer cells and reveal metabolic vulnerabilities that can be targeted. Notably, glutamine is the most
abundant aminoacid in human serum and is essential for many cancer cells to generate TCA cycle
intermediates and support the biosynthesis of nucelotides, N-acetyl glucosamines, fatty acids, GSH and
other aminoacids [254]. Intriguingly, NRF2 can control different steps of glutamine fate, from its uptake
to its metabolism. For example, early studies reported that NRF2 can induce the expression of the
glutamine importer SLC1A5 in HeLa cells through the ATF4 transcription factor [256] while a recent
ChIP-Seq analysis on KEAP1-/- mice and human ESCC cells, revealed that NRF2 causes metabolic
reprogramming by enhancing the expression of the SLC1A4 glutamine transporter and other metabolic
enzymes [257]. Lastly, the enzyme glutaminase, catalyzing the conversion of glutamine into glutamate,
was found to be a direct NRF2 target gene in MCF7 and MCF10 BC cells treated with Sulforaphane or
subdued to KEAP1 KD by siRNA [258]. Therefore, NRF2 is profoundly implicated in the control of
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glutamine metabolism of cancer cells and most likely this regulatory node will be the focus of extensive
research in the next future.
3.1.7. NRF2 in the Regulation of Fatty Acids Metabolism
Interestingly, NRF2 has been found to exert opposite changes in the metabolism of fatty acids,
since a repression of FAS (fatty acid synthesis), but a stimulation of FAO (fatty acid oxidation) has
been reported in isolated mitochondria, MEFs (mouse embryonic fibroblasts) and tissues of transgenic
mice [259]. Despite the lack of data on malignant tumors a study on HEK-293T cells suggests
that NRF2 might control the expression of CPT1 and CPT2, two isoforms of the enzyme carnitine
palmitoyltransferase (CPT) that catalyzes the rate-limiting step of FAO [260]. Another mechanism by
which NRF2 can potentially support the redox balance of cancer cells is through the suppression of
NADPH-consuming processes, including lipid biosynthesis. Indeed, by using murine models with
variable NRF2 expression, Wu et al., showed that NRF2-null mice exhibited increased hepatic mRNA
levels of the enzymes fatty acid synthase (FASN), fatty acid desaturase (FADS1, FADS2), stearoyl-CoA
desaturase (SCD1), fatty acid elongases (ELOVL2,3,5,6 and CYB5R3), acetyl-CoA carboxylase-1 (ACC1)
and ATP-citrate lyase (ACLY), while the opposite was seen in KEAP1-KO mice suggesting that
NRF2 restrains lipogenesis and desaturation to prevent NADPH depletion [261]. On the other hand,
NRF2 activation in mouse lung was conversely seen to induce the transcription of FAO genes and
lipases, promoting degradation of damaged lipids and providing reducing equivalents in the form of
NADPH [262]. In conclusion, the activity of NRF2 can significantly affect the efficiency of FAO and
lipid biosynthesis, ultimately affecting bioenergetics as well as NADPH-linked antioxidant systems,
underscoring the intimate connection between metabolic processes and redox homeostasis.
3.2. Strategies to Negatively Modulate NRF2 Signaling/Pathway
Tumors are complex entities composed by heterogeneous cell populations that dynamically adapt
to their microenvironment driven by genetic/epigenetic alterations and metabolic rewiring [263–267].
Thus, cancer cell populations that become prevalent during certain phases of the malignant progression
can frequently develop resistance to treatment [268–271]. Moreover, due to patients’ individualities
and tumors heterogeneity, variable response rates are often observed making the identification of more
effective drugs very urgent [272,273]. In this regard, the concomitant inhibition of antioxidant circuits
and metabolic pathways that support the redox balance of malignant cells, delineates a promising
anti-cancer strategy [274–283]. It is known that most of the metabolic changes promoting cancer
cells proliferation and tumor growth induce also an increased ROS generation, counterbalanced
by an antioxidant response that prevents cell death [234,284,285]. Of note, since the cytotoxicity
of conventional anti-cancer therapies largely relies on efficient ROS accumulation, the augmented
antioxidant capacity of cancer cells constitutes a key determinant of therapy-resistance [286–288].
At the same time, given the strong dependency of malignant cells to their antioxidant systems,
interfering with their redox control can induce OS-dependent cell death [289]. Since the NRF2 signaling
plays a key role in tumorigenesis, malignant progression [290–292] and drug sensitivity [293–295],
this transcription factor has emerged as a promising therapeutic target [16,282,296–298]. In this regard,
several studies have tried to identify NRF2 activators to prevent ROS-dependent carcinogenesis while
others have focused on the development of NRF2 inhibitors to overcome therapy resistance [299–301].
In the following sections, the most promising NRF2 inhibitors, described so far in the literature, will
be presented.
3.2.1. Natural Compounds That Impair NRF2 Signaling by Interfering with Protein Synthesis
Despite the increasing demand for negative modulators of NRF2, selective inhibitors are
neither currently available nor under clinical trial evaluation. Yet, alternative strategies have been
explored based on the pharmacologic manipulation of various NRF2 modulators through natural
and synthetic compounds [302,303]. Historically, many natural compounds have been used to
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treat human pathologies, including cancer. Importantly, these compounds have been often used to
potentiate the efficacy of ROS-inducing agents against therapy-resistant cancers, by altering their
redox homeostasis. Among the others, many studies focused on Brusatol, a quassinoid from the
plant Brucea javanica [304–306], and its derivatives [307,308]. The antitumor effects of Brusatol have
been ascribed both in solid and in hematologic tumors to the inhibition of proliferation and the
disruption of antioxidant defenses caused by NRF2 depletion, due to global suppression of protein
synthesis [309–311]. For instance, in A549 NSCLC cells resistant to radiation, Brusatol was found to
dose-dependently decrease the NRF2 protein levels and to enhance the efficacy of ionizing radiations,
by inducing ROS-dependent DNA damage and cell death [312]. Also, Brusatol was recently found
to impair cell growth and proliferaton of human A375 melanoma cells both in vitro and in vivo
(NOD/SCID xenografted mice) when used in combination with UVA treatment, leading to increased
ROS generation and apoptosis due to AKT impairment [313]. Also, Karathedath et al., reported that
NRF2 overexpression in AML cell lines and primary AML samples caused resistance to Cytarabine,
Daunorubicin and Arsenic trioxide (ATO). Importantly, Brusatol was found to markedly decrease the
NRF2 content and consequently the expression of its target genes GCLC, GCLM, HMOX-1, and NQO1,
promoting ROS accumulation and apoptosis [314]. Finally, in a recent study from Xiang et al., the
overactivation of NRF2 signaling was found to mediate Gemcitabine resistance in human PANC-1,
PATU-8988 and BXPC3 pancreatic ductal adenocarcinoma cancer (PDAC) cell lines. Here, Brusatol
induced ROS accumulation, growth inhibition and apoptosis by decreasing the protein levels of
NRF2 and its target genes HO-1 and NQO-1. Notably, Brusatol enhanced the antitumor activity of
Gemcitabine in vivo by reducing the growth rate of PANC-1 xenografts implanted in BALB/c nude
mice [315]. Similarly, other work has been directed to Halofuginone from the plant Dichroa febrifuga,
which is rapidly emerging as one of the most promising NRF2 inhibitors. Indeed Halofuginone has
been shown to impair proliferation, migration and invasion of HepG2 HCC cells [316] and MCF7 BC
cells [317,318], to reverse the radioresistance of Lewis lung cancer cells (LLCC) [319], or to improve the
drug delivery in PDAC cells [320]. In a recent study from Tsuchida K. et al., Halofuginone was seen
to repress protein synthesis through prolyl-tRNA synthetase inhibition and to prevent NRF2 nuclear
accumulation causing the impaired expression of enzymes involved in drug metabolism and transport,
iron metabolism, GSH metabolism and ROS scavenging. As a result, KYSE70 human esophageal
cancer (HEC) or A549 NSCLC cells, became more susceptible to Cisplatin based on in vitro and in vivo
experiments, with limited side-effects [321]. It should be emphasized that Halofuginone has a very
similar mechanism of action to that of Brusatol, confirming that the inhibition of protein synthesis
remains a valid strategy to block NRF2 signaling.
3.2.2. Natural Compounds That Impair NRF2 Signaling by Acting on Functional Regulators
Other works have explored the potential use of Chrysin, a natural flavone found in many plant
extracts such as honey, propolis, and blue passion flowers, endowed with anticancer effects against
different tumors [322,323]. In an earlier study on BEL-7402 human HCC cells resistant to Doxorubicin,
Chrysin significantly reduced NRF2 expression both at the mRNA and protein levels, by interfering
with PI3K/AKT and ERK pathways. As a result, the expression of NRF2-related target genes HMOX-1,
AKR1B10 and MRP5, was significantly reduced and the chemoresistance attenuated [324]. In another
work form Wang J. et al., Chrysin was seen to suppress the proliferation, migration and invasion
of human T98, U251 and U87 glioblastoma (GBM) cells and to abrogate the in vivo tumorigenicity
of U87 xenografts in BALB/c mice. Mechanistically, Chrysin impaired NRF2 nuclear translocation,
by decreasing the protein levels of phospho-extracellular signal-regulated kinase-1/2 (ERK1/2) and two
antioxidant enzymes HO-1 and NQO-1 [325].
3.2.3. Natural and Synthetic Compounds Blocking NRF2 Pathway by Still Unknown Mechanisms
Oridonin, a diterpenoid isolated from the herb Rabdosia rubescens, represents another promising
compound whose potent antitumor effects have been described in leukemia [326], BC [327] and CRC
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cells [328]. Very recently, Oridonin was found to promote mitochondrial-dependent apoptosis by
activating PPARγ and suppressing both NF-κB and NRF2 pathways in MG-63 and HOS osteosarcoma
cells. Here, Oridonin prevented NRF2 nuclear translocation and decreased the expression of the
HMOX1, NQO1 genes and their encoded antioxidant proteins, leading to ROS-dependent apoptosis,
in vitro and in vivo [329]. Also Plumbagin, a natural naphthoquinone from Plumbago zeylanica L.,
has received substantial attention as a potent inducer of apoptosis in pancreatic, lung, breast and
prostate cancer cells caused by ROS overproduction [114,330]. With this respect, by using human
ovarian (OVCAR3), breast (SKOV3, MCF7), and endometrial (ECC1) cancer cells, a recent study
has shown that Plumbagin promotes ROS generation via the mETC complexes I-III and synergizes
with Brusatol to block NRF2 pathway, triggering cell death [331]. In another work, a SILAC-based
quantitative proteomic approach was used to characterize the biological changes induced by Plumbagin
in SCC25 tongue squamous cell carcinoma (TSCC) cells. Here, Plumbagin was seen to decrease the
NRF2 nuclear translocation and to suppress the induction of its target genes. As a result, unbalanced
ROS overproduction led to cell cycle arrest and stemness attenuation, triggering apoptosis [332].
Extensive research has also been pursued on the alkaloid Trigonelline, a coffee extract initially identified
as a negative modulator of NRF2 signaling in HT29 human colorectal cancer cells (CRC), with the ability
to decrease the nuclear and total content of NRF2 and to inhibit its target genes transactivation [333].
In a later study, the effects of Trigonelline on NRF2-mediated apoptosis evasion were studied in
MiaPaca2, PANC-1, and Colo357 PDAC cell lines and in the human pancreatic duct cell line H6c7. Here,
Trigonelline was shown to strongly suppress NRF2 activity by preventing its nuclear accumulation and
to increase the efficacy of TRAIL and Etoposide both in vitro and in vivo, with few side-toxicity [334].
Importantly, three different studies from the group of Shin D. recently focused on the impact of
Trigonelline on chemoresistance by using experimental models of HNC. First, using HNC cells
resistant to Cisplatin, Trigonelline was found to restore the chemosensitivity of HN 2-10 and SNU
cells both in vitro and in vivo when combined with inhibitors of GSH synthesis and TRX system [287].
Interestingly, in the same experimental model, NRF2 was seen to promote resistance to the ferroptosis
inducer Artesunate, while conversely the combination with Trigonelline resulted in strong cytotoxicity
due to ROS accumulation. Remarkably, the effect was restricted to Artesunate- or Cisplatin-resistant
HNC cells, sparing normal oral keratinocytes and oral fibroblasts [301]. Lately, the same group reported
that in HNC cells, suppression of NRF2 signaling by Trigonelline could reverse the resistance to
ferroptosis both in vitro and in vivo [335]. Thus, Trigonelline is emerging as a promising molecule
for combination regimens against tumors with widespread chemoresistance. Importantly, the use
of high throughput screening (HTS) has played a major role in the discovery of NRF2 inhibitors.
For example, AEM1, a benzodioxole substituted analog recently identified in A549 NSCLC cells,
was seen to strongly suppress NRF2-mediated genes expression, without altering NRF2 protein stability,
its phosphorylation or the KEAP1 content. Importantly, AEM1 reduced the growth rate of A549
NSCLC cells both in vitro and in vivo, enhancing also their sensitivity to Etoposide and 5-Fluorouracil.
Of note, AEM1 was also able to decrease the NRF2-dependent induction of HMOX1 in H838 and H460
NSCLC cells with LOF mutations of the KEAP1 gene, suggesting that AEM1 might preferentially target
tumor cells with constitutive NRF2 activation [336]. Similarly, Singh et al., conducted a quantitative
high-throughput screening (qHTS) of the Molecular Libraries Small Molecule Repository (MLSMR)
and identified a compound named ML385 that was able to reduce the transcriptional activity of NRF2
by preventing the binding of the NRF2-MAFG complex to the ARE sequence in the promoter of NSCLC
cells. More in detail, ML385 attenuated NRF2 pathway by affecting the DNA binding activity of the
NRF2-MAFG protein complex through direct interaction with NRF2. As a result, ML385 induced
selective toxicity in both A549 and H460 NSCLC cells harboring KEAP1 mutations, enhancing the
cytotoxic effects of Doxorubicin, Carboplatin and Paclitaxel without affecting the non-tumorigenic
BEAS2B cells. Importantly, the therapeutic efficacy of ML385 as a single agent and in combination with
carboplatin was also confirmed in orthotopic lung cancer xenografts subcutaneously implanted in nude
mice [25]. Moreover, in a very recent study from Hori R. et al., the K-563 compound was isolated from
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Streptomyces sp. after HTS screening of almost 10000 culture broth samples. Of note, K-563 abrogated
the expression of NRF2 target genes such as GCLC, GCLM, AKR1C1 (reductase family 1 member C1),
ME1, NQO1 and TXNRD1 in A549 NSCLC cells and in the human gallbladder cancer (GBC) cell
line TGBC24TKB, without altering the NRF2 protein levels, its ARE-binding ability, or its nuclear
localization. As a result, K-563 promoted ROS accumulation and synergized with either Cisplatin or
Etoposide in A549 NSCLC cells, suppressing also cell proliferation in GBC cells (TGBC24TKB) without
affecting normal human lung cells (BEAS-2B) [337]. In the context of hematologic tumors, Zhang et al.,
identified 4f, a pyrazolyl hydroxamic acid derivative with potent antineoplastic effects in human
THP-1, HL60 and U937 AML (acute myeloid leukemia) cells. Here, 4f was found to decrease the NRF2
protein content and the mRNA levels of HMOX1 and GCLC genes, promoting increased caspase-3
and PARP cleavage. Besides, 4f suppressed the growth of THP-1 xenografts seeded onto the CAMs of
chicken eggs and also impaired blood vessels formation in vivo in a gelatin sponge assay, suggesting
that 4f might be a promising treatment in advanced AML [338]. In summary, very promising results
have been reported in case of repressors of protein synthesis, an evidence that might pave the way to
the design of novel strategies to target the NRF2 pathway in cancers. Taken together, these studies
provide a strong rationale for the identification and validation of compounds with the ability to disrupt
the redox control exerted by NRF2 in solid as well as hematologic tumors. Moreover, it is expected that
other experimental work as well as refined clinical trials will better define the molecular mechanisms,
the specific context and the types of tumors wherein this approach might ensure the optimal efficacy in
patients with advanced cancers.
3.2.4. Natural and Synthetic Compounds Targeting Functional Regulators of the
NRF2-KEAP1 Pathway
An alternative strategy to hamper the pro-tumoral effects of NRF2 is through the modulation of
functional regulators that ultimately converge on this signaling pathway. This approach offers at least
two significant advantages. First, it relies on already established drugs with proven anticancer activity
and, more importantly, it does not require selective NRF2 inhibitors. Of note, recent work supports
the applicability of this strategy. For example, LGK-974, a specific inhibitor of the O-acyltransferase
porcupine (PORCN) used to disrupt the WNT signaling, was recently found to prevent NRF2 nuclear
translocation and its expression in HepG2 cells, presumably by impairing the WNT3A-dependent
formation of the GSK-3/β-TrCP protein complex. As a result, the HepG2 cells were sensitized to
otherwise non-toxic radiation doses, due to downregulation of NRF2 target genes such as HMOX1
and NQO1 and increased ROS production [339]. Also Wogonin, a flavonoid isolated from Scutellaria
baicalensis Georgi, has emerged as a promising anticancer agent, due to its chemosensitizing ability in
Doxocycline-resistant MCF7 BC cells [340]. Further investigations revealed that Wogonin reduced the
NRF2 nuclear translocation and promoted increased ROS production, potentiating the cytotoxicity of
Hydroxy-Camptothecin, Cisplatin and Etoposide also in HepG2 cells [341]. Other work was conducted
on chronic myelogenous leukemia (CML) cells sensitive (K562) or resistant (K562/AO2) to Adriamycin
(ADR). As first, Wogonin was found to decrease the NRF2 mRNA and protein levels in CML cells,
causing a marked reduction in the HO-1, NQO1 and MRP1 proteins [342]. In a later work the same
authors showed that Wogonin could decrease the binding of both p65 and p50 NF-kB subunits to
the NRF2 promoter in K562/A02 cells, enhancing their sensitivity to ADR. In vivo, transplantation
experiments of K562/A02 cells into NOD/SCID mice proved that the combination of ADR and
Wogonin could reduce the nuclear content of NF-κB p65 and NRF2 [343]. Hence, Wogonin represents
a promising inhibitor of NRF2 and a potent chemosensitizer in solid and hemathologic tumors.
Also, Gao et al., explored the anti-cancer potential of Apigenin, a natural bioflavonoid found in
many fruits and vegetables. As first, Apigenin was seen to reduce the expression of NRF2 and its
targets HO-1, AKR1B10 and MRP5 both at the mRNA and protein levels in a KEAP1-independent
way, by downregulating the PI3K/AKT pathway and to strongly sensitize BEL-7402/ADM cells to
Doxorubicin both in vitro and in vivo, blocking tumor growth [344]. Additional work, led to the
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identification of the microRNA mir-101, as a modulator of NRF2 functions in HCC cells. Here,
mir-101 was found to be downregulated in BEL-7402/ADM (resistant) and conversely highly expressed
in BEL-7402 (sensitive) cells, while the NRF2 mRNA sequence analysis revealed the presence of
a complementary site for mir-101 in the 3’-UTR. Importantly, mir-101 mimics markedly decreased
the NRF2 protein levels in BEL-7402/ADM cells exerting chemo-sensitizing effects, while opposite
changes were induced by antimir-101. Collectively, these data indicate that mir-101 re-expression
might be a novel mechanism to blunt NRF2 signaling in HCC resistant cells [345]. Also, Retinoic
acid, a Vitamin A metabolite, has emerged as a potential anticancer agent inducing differentiation,
growth arrest, and apoptosis of cancer cells [346]. Initial studies on solid tumors have shown that
All-Trans Retinoic Acid (ATRA) can induce RARα expression, which in turn forms a protein complex
with NRF2 and antagonizes its transactivation [347,348], sensitizing chemoresistant neuroblastoma
(NB) HTLA-230 cells to the proteasome inhibitor Bortezomib [349]. Other experimental work from
Valenzuela M. et al., extended these observations to AML and APL cells treated with the ROS-inducer
Arsenic Trioxide (ATO). Here, the combined use of ATRA and ATO was seen to prevent NRF2
nuclear translocation and to suppress the antioxidant response in HL-60 and THP-1 AML and in
NB4 APL cells, inducing cytotoxicity. Additionally, the authors also showed that the ATRA-mediated
inhibition of NRF2 depended on RARα, since ATRA was ineffective when parental NB4 cells were
pre-treated with the RARα antagonist Ro-41-5253 or when applied to mutant NB4-R2 cells lacking
RARα expression [350].
4. Conclusions and Future Perspectives
Since its discovery in 1994 [27] NRF2 has been connected to various cellular mechanisms, such as
response to oxidative stress, mitochondrial respiration, stem cell quiescence, mRNA translation and
autophagy [51]. The NRF2-KEAP1 pathway is a master regulator of cell protection mechanisms against
exogenous or endogenous stress sources. Thus, in the past decade, NRF2 has emerged as an important
target in cancer therapy. Many questions have arisen in relation to risks and benefits of negative
modulators of NRF2 signaling. Recent research suggest that suppression of antioxidant mechanisms
involving NRF2 might potentially induce a pro-oxidizing shift in tumor microenvironment and promote
ROS-dependent cell death in many cancer types. Despite the absence of specific and selective NRF2
inhibitors, convincing indications show that the use of natural compounds with known therapeutic
action might be effectively used in different types of tumors [351,352]. NRF2 has been recognized as one
of the critical factors regulating an array of genes that protect cells against xenobiotics. NRF2-mediated
transcriptional regulation is coordinated by a number of specific events within the cellular environment.
Among them, the triggering stimulus, the cooperation with other activators and repressors, the interplay
with different signaling pathways and the epigenetic landscape of the target gene promoters, can be
regarded of utmost importance. Many approaches have been devised to target the NRF2 signaling
pathway in cancer such as regulating NRF2 expression at the transcriptional level, controlling the
NRF2 nuclear translocation, targeting the KEAP1-NRF2 binding for modulating NRF2 protein stability
and regulating NRF2 binding to its target genes promoters. Several small-molecule NRF2 activators
and inhibitors have been developed and successfully employed in cancer treatment. The important
drawbacks of targeted therapy include resistance of cancer cells and difficulties of developing drugs to
some tumor-specific targets [191,353]. Studies suggest that in tumors, high levels of NRF2 can occur in
absence of genomic alterations in the NRF2 and KEAP1 genes. Additional research will help to increase
the specificity of NRF2-based therapies. For example, crystallographic investigations of KEAP1 might
provide chances to design and synthesize molecules that selectively interfere with the KEAP1-NRF2
binding [354]. Moreover, accumulating evidence suggests that NRF2 can interact with other pathways
implicated in cell survival [355]. These important points offer great opportunities for pharmacological
intervention to control the level of NRF2 and its therapeutic effects. NRF2 was firstly described as a
tumor suppressor involved in the inhibition of tumor initiation and cancer metastasis. Recent evidence
showed that it can also act as a pro-oncogenic factor. It is now well accepted that NRF2 has a dual role
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in carcinogenesis and that pharmacological induction of the NRF2 pathway might be chemopreventive
in the early stages of tumorigenesis. However, adverse effects might occur in advanced stages of cancer
by inducing therapy resistance [356,357]. Chemotherapy resistance is one of the crucial problems
for the effective treatment of many cancers, and NRF2 inhibition might be a promising approach to
overcome this phenomenon. Being located at the crossroad of many defensive pathways influencing
cell life during chemical, oxidative, and metabolic stress, the NRF2-KEAP1 pathway has been the focus
of broad research aimed at revealing its role in cancer [105]. Aberrant activation of the NRF2-KEAP1
pathway is often recognized in many tumors, promoting cancer growth, survival, metastasis formation
and therapy resistance [358,359]. It is known that NRF2 activation in response to oxidative stress
promotes cells survival. NRF2 also induces metabolic changes that sustain cell proliferation. Because
of these benefits, cancer cells with sustained NRF2 activation frequently develop “NRF2 addiction” [3].
Disruption of NRF2 signaling is a promising therapeutic approach against NRF2-addicted cancers and
some effective NRF2 inhibitors such as brusatol and halofuginone have been employed, while many
others are under investigation. Nevertheless, administration of systemic NRF2 inhibitors may cause
off-target effects on patients and this represents a key aspect for the identification of novel compounds
that should ideally possess high specificity, bioactivity and limited side-toxicity [26]. To prevent these
side effects, mechanistic insights should be revealed and new pharmacological targets besides NRF2
should be studied. Depending on metabolic fluxes of NRF2-addicted cancer cells, thorough metabolite
examination might help to identify specific diagnostic markers. Research have suggested that the
over-activation of NRF2 promotes tumor development, prevents cell apoptosis and enhances the
therapy-resistance of cancer cells. We know that both NRF2 inducers and NRF2 inhibitors possess
anticancer activity against different targets. NRF2 inducers protect normal cells from carcinogen
effects, while NRF2 inhibitors halt cancer cells proliferation. The question is what we need exactly,
NRF2 activators or inhibitors? According to the numerous recent studies related to the oncogenic
activity of NRF2, the synthesis of novel selective inhibitors of NRF2-KEAP1 pathway could be the
better strategy for cancer prevention and therapy [64]. The dilemma of whether NRF2 can be used
as a pharmacological target needs to be harmonized with the research of clinical application and
participation of mediators of oxidative stress in the anticancer therapy. In conclusion, the discovery,
design, and synthesis of NRF2-centered methodologies are important and challenging tasks that might
pave the way to novel therapeutic approaches in cancer treatment.
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